Image Source: ISRAELVALLEY
Read more »

Labels: Study

Image Source: 43 RUMORS

CONCERTO and ARPEGGIO Trials Continue Study of Lower-dose Laquinimod

Jerusalem & Lund, Sweden - January 4, 2016 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ Stockholm: ACTI) today announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients.
Read more »

Image Source: PINTEREST
Read more »

Labels: Study

Image Source: BING
Read more »

Labels: Aubagio, Study

By Kim Dolce—December 8, 2015

December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »

Labels: Aubagio, Avonex, Betaseron, Gilenya, Rebif

Copaxone, marketed by Takeda, is already approved for use in some 50 countries

Takeda Pharmaceutical Co. Ltd., a pharmaceutical company based in Osaka, Japan, recently announced that a widely approved drug treatment for the prevention of relapses in multiple sclerosis (MS) is now available in Japan as well.
Read more »

Read more »

Labels: Study

Image Source: THECAREFREETRAVELER

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day, recently announced the approval of a Marketing Authorization license (MA) by the Russian Ministry of Health for three-times-per-week COPAXONE®(glatiramer acetate injection) 40 mg/mL, a new dose of COPAXONE®, to treat patients with a diagnosis of relapsing-remitting multiple sclerosis (RRMS). This new COPAXONE® formulation will reduce the frequency of dose regimen for RRMS patients in Russia.
Read more »

ISRAELVALLEY
Read more »

Labels: Study

Image Source: ISRAELVALLEY

According to a press release from Mylan N.V., the U.S. Patent and Trademark Office (PTO) has issued an inter partes review (IPR) proceeding on all claims against a third Copaxone patent for the 40 mg/mL (U.S. Patent No. 8,969,302) formulation by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The news represents continued patent challenges and efforts by other pharmaceutical companies to produce generic forms of Copaxone, which is a leading multiple sclerosis therapy for the relapsing-remitting form of the disease.
Read more »

Image source: PREVENTDISEASE
Read more »

Labels: Study

Image source: DRUGDISCOVERY

Cambridge-based Momenta Pharmaceuticals and partner Sandoz announced plans late yesterday to launch the first generic drug in the U.S. to treat multiple sclerosis, priced 15 percent less than the branded version of the drug.
Read more »

Image source: PHARMAFILE
Read more »

Labels: Study

In a relief to Natco Pharma, the US court of appeals has invalidated Teva’s Copaxone patent. This may help generic pharma companies to launch one of the top-selling multiple sclerosis drugs, Copaxone.
Read more »

Image source: UCRTODAY

The first generic version of a multiple sclerosis drug went on the market Thursday, hours after a federal appeals court again invalidated a patent for the brand-name drug, Copaxone, a major moneymaker for Teva Pharmaceutical.
The generic drug, which will be made by Sandoz and Momenta Pharmaceuticals and will be called Glatopa, was approved by the Food and Drug Administration in April but the companies held off starting sales, apparently waiting for the court to rule on the patent.
Read more »

Image source: MYELITETMOI
Read more »

Labels: Study

Read more »

Labels: Study

Read more »

Labels: Study

Read more »

Labels: Gilenya, Study

The U.S. Food and Drug Administration has approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).
Read more »

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011

Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan.
Read more »

Read more »

Labels: Aubagio, Avonex, Betaseron, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next five years, our analysts believe their sales could dwindle to a trickle.
Read more »

Foreign exchange rates and generic competition for its multiple sclerosis blockbuster Copaxone has led Teva Pharmaceutical Industries to making 2015 forecasts below analysts' expectations.
Read more »

Read more »

Labels: Avonex, Betaseron, Rebif, Study

Read more »

Labels: Gilenya, Study

The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an ´oral revolution´ has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.
Read more »

Labels: Avonex, Betaseron, Rebif

When I typed the title of this blog post I was saying to myself, laaaaaawwwww breaker, using a Matthew McConaughey legal thriller voice.   What does Matthew’s southern accent have to do with this blog?
Read more »

A lower-cost version of one of the mainstays of first-line multiple sclerosis treatment appears poised to win marketing approval on the basis of pivotal trial results, and the marijuana derivative known as Sativex was, for the first time, shown to improve an objective measure of spasticity in a randomized trial. The studies were presented recently at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held jointly this year with its North American counterpart, ACTRIMS.
Read more »

Labels: Medical Marijuana, sativex

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington's disease. Currently, there are no approved therapies available for the treatment of PPMS or the treatment of Huntington's disease, beyond symptom management.
Read more »

Dividend stocks are a pivotal part of a balanced portfolio because they provide income and can help to lower the average purchase price of shares over time through dividend reinvestment plans.
Read more »

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data on COPAXONE® (glatiramer acetate injection) and laquinimod, an investigational therapy for multiple sclerosis (MS), will be featured at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, September 10 – 13, 2014.
Read more »

Dr. Rhonda Voskuhl, M.D.

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimesta™, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to present additional clinical outcome data, including more detailed results on cognitive and disability measures. The data will be presented at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.
Read more »

Labels: Trimesta

The US multiple sclerosis market is expected to evolve notably in 2014, with analysts now confident that the FDA will approve at least one generic version of Teva´s Copaxone when exclusivity expiries in May.
Read more »

The hormone is a form of estrogen called estriol. It's abundant in a woman's body only when she is pregnant. Adding estriol to treatment with an existing MS drug cut relapses by 47 percent in a study of 158 women presented at the American Academy of Neurology meeting in April.
Read more »

Labels: Pregnancy

Teva and Active Biotech filed a request for a review of the finding. The result is a setback for the two companies. Laquinimod has been considered a replacement for Teva's high-selling multiple sclerosis treatment Copaxone
Click here to read more

Labels: Laquinimod (Nerventra)

Read more »

Labels: Laquinimod (Nerventra)

Read more »

Labels: Lemtrada

Read more »

Labels: Avonex, Betaseron, Rebif, Study

Read more »

Labels: Gilenya, Study

Teva is stubbornly defending its blockbuster multiple sclerosis drug Copaxone, talking up gene expression data and the safety concerns of generic variants. But rival Mylan says it has engaged diligently with the FDA and that, barring administrative hurdles, it may be closer to final approval.
Story Source: The above story is based on materials provided by Pharmamedtechbi
Note: Materials may be edited for content and length
Click here to read original article

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data on COPAXONE® (glatiramer acetate injection) and laquinimod, an investigational therapy for multiple sclerosis (MS), will be featured at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, September 10 – 13, 2014.
Read more »

COPENHAGEN -- Teriflunomide (Aubagio) significantly reduced the risk of clinically definite multiple sclerosis in patients who had suffered a first bout of symptoms, an academic researcher confirmed here.
Read more »

Labels: Aubagio

Latest Comments
From Subject Time Posted
1 NEW! » Jeannine Elan Extends Tysabri's Reach to Canada Oct 8 2006 07:46
1 NEW! » Jeannine 10 Top Australian Scientists Predict Major Medical Advances in MS (download free report) Oct 10 2006 13:11
1 NEW! » Jeannine NEUROVAX: PRESS RELEASE FROM IMMUNE RESPONSE CORP. Oct 10 2006 13:06
1 NEW! » "Gamma Julie" Should Job Hunters Reveal Chronic Illness? The Pros and Cons..[update] Oct 31 2006 03:41
1 NEW! » Jeannine HUMAN STEM CELLS DELAY START OF LOU GEHRIG'S DISEASE IN RATS Oct 15 2006 10:02
1 NEW! » Jeannine Tysabri and Avonex add customer service reps Oct 17 2006 07:34
1 NEW! » Jeannine "Take 10 laps and call me in the morning" Oct 17 2006 09:15
1 NEW! » Jeannine "inmate moved to hospital" (AN UPDATE OF LAST WEEKS STORY: "INMATE WITH MS" Oct 17 2006 09:42
1 NEW! » Jeannine Fampridine SR - NEW DRUG IN PIPELINE Oct 18 2006 09:42
1 NEW! » Jeannine [PROFESSIONAL ABSTRACT] Oct 18 2006 09:43
1 NEW! » David "Copaxone allows some MS patients to retain mobility" Oct 19 2006 19:50
1 NEW! » Lora Future-directed thinking and depression in MS [READ LIZZY'S COMMENT!!!] Oct 28 2006 15:03
1 NEW! » Jeannine MS BIKE TREK Oct 19 2006 09:38
1 NEW! » WaterDragon STEM CELL: "Federal government promotes donation of umbilical cords for stem cell transplants" Oct 20 2006 00:51
1 NEW! » Jeannine Development of an anti-IL-17A auto-vaccine... Oct 20 2006 09:05
1 NEW! » Jeannine GREAT PERSONAL STORY: Oct 20 2006 15:17
1 NEW! » Jeannine "Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone" Oct 20 2006 15:21
1 NEW! » Jeannine The Effect of dose and frequency of interferon beta-1a administration Oct 20 2006 15:31
1 NEW! » Jeannine CDP323: NEW DRUG IN PIPLINE Oct 21 2006 09:58
1 NEW! » Jeannine Did you know that Colorado has one of the highest prevalence rates of MS in the US Oct 21 2006 09:59
1 NEW! » Jeannine Write in Candidate Denise Clement will work for free! Oct 21 2006 10:00
1 NEW! » Jeannine Methylthioadenosine Effective in Animal Models of Multiple Sclerosis Oct 22 2006 07:32
1 NEW! » Jeannine UK: cannabis pill test Oct 22 2006 07:34
1 NEW! » Jeannine Clustering of autoimmune diseases in families with a high-risk for MS: Oct 23 2006 07:36
1 NEW! » Jeannine The female to male sex ratio by year of birth has been increasing for at least 50 years Oct 23 2006 07:39
1 NEW! » Jeannine Photography studio is donating fees to MS Oct 23 2006 08:17
1 NEW! » Jeannine Boston Home's 125th Anniversary - Oct 24 2006 09:28
1 NEW! » Jeannine UK...MP's Back MS Campaign Oct 24 2006 09:32
1 NEW! » Jeannine Dutch prosecutors ask highest court to quash appeals court medicinal cannabis decision Oct 24 2006 09:34
1 NEW! » Jeannine MBP8298 Oct 24 2006 09:35
1 NEW! » deleted account Live HealthTalk - 30 Minutes of Q&A with Nurse Piper [sponsored by a drug company] Oct 24 2006 19:50
1 NEW! » Jeannine High-Dose Cyclophosphamide Study: GOOD RESULTS!!! Oct 25 2006 09:32
1 NEW! » Jeannine NEW DRUG IN PIPELINE: MCT-125 Oct 25 2006 09:35
1 NEW! » Jeannine 3 Guys, 3 Bikes, 7,000 Miles Through South America for MS Oct 25 2006 09:39
1 NEW! » Jeannine 14-year old bicyclist rides for MS Oct 26 2006 08:24
1 NEW! » Jeannine Accelerated Cure Project for MS today announced the formation of their MS Repository Oct 26 2006 08:29
1 NEW! » Jeannine A MSnewsChannel.com Video: A TIP FROM HEATHER ON EASING REBIF PAIN Oct 26 2006 09:02
1 NEW! » Jeannine TYSABRI® GOOD FOR LUPUS TOO...PER THIS PRESS RELEASE FROM ELAN Oct 26 2006 09:04
1 NEW! » Jeannine VISIT OUR "TYSABRI NEWS" WEBSITE Oct 26 2006 09:08
1 NEW! » Jeannine Joseph Eisen suffers from Primary Progressive Multiple Sclerosis....AGENGY HELPS WITH HIS LEGAL Oct 27 2006 08:18
1 NEW! » Jeannine Campus Fudraiser....(good idea for other colleges) Oct 27 2006 14:22
1 NEW! » David WATCH VIDEO: Selling CDs as a MS Fundraiser Oct 29 2006 09:03
1 NEW! » Jeannine If a sibling has MS, you are 15 to 25 times more likely to develop it yourself Oct 29 2006 09:16
1 NEW! » Jeannine UK: NO JAIL FOR HUSBAND WHO HELPED WIFE'S SUICIDE Oct 29 2006 09:18
1 NEW! » Jeannine Car enthusiasts, bikers rally MS Oct 29 2006 09:26
1 NEW! » Jeannine UPDATE ON MS CANDIDATE WHOSE OPPONENT MADE A NASTY WHEELCHAIR COMMENT Oct 30 2006 08:32
2 NEW! » Jeannine "MS NO LONGER A DEATH KNELL FOR PATIENTS" Oct 30 2006 08:43
2 NEW! » David WATCH VIDEO PLUS FREE READ OF CHAPTER 1 : Today show host Meredith Vieira talks with Teri Garr Oct 30 2006 20:27
1 NEW! » WaterDragon "Ed Johns says he feels like a new man" [I WOULDN'T LET MY SON DO THIS!-stan] Oct 31 2006 01:11
1 NEW! » Jeannine TYSABRI.....Biogen Idec Third-Quarter Net Rises Sixfold on MS Drugs Oct 31 2006 09:18
1 NEW! » Jeannine DETROIT FUNDRAISER Nov 1 2006 10:08
1 NEW! » Jeannine ABSTRACT FOR DOCS, NURSES Nov 1 2006 10:09
2 NEW! » Jeannine .....control of their health with exercise, even though it might bring short-term discomfort Nov 1 2006 15:05
1 NEW! » Darth Woky ™ GREAT READ: MS afflicts about twice as many females as males Nov 2 2006 01:15
2 NEW! » David Cladribine used to treat some cancers and possibly MS: Brigham Young University Nov 2 2006 19:15
2 NEW! » David I JUST RECEIVED THIS PRESS RELEASE FROM TEVA RE: COPAXONE {NOT IMPORTANT :-)] Nov 2 2006 19:23
2 NEW! » David VOTE: ANOTHER STEM CELL STORY(I can't decide if I should post stem cell stories or not?? -stan) Nov 2 2006 19:33
3 NEW! » David update: DRUG DELAYED BY FDA FOR A MS CONDITION I'VE NOT HEARD OF -HAVE YOU??? -stan Nov 2 2006 19:36
2 NEW! » David MS Linked to Abnormal Liver Test Results Nov 2 2006 19:46
1 NEW! » Rev. cutthroat carnie TYSABRI BAD NEWS:Since July, only 47 of more than 8,500 patients are using Tysabri... Nov 7 2006 08:13
1 NEW! » Jeannine New York City Chapter MS Society: Help Us Reach Our Fundraising Goal for the MS Bike Tour Nov 1 2006 14:43
1 NEW! » Jeannine BAD NEWS ON UCLA PLAYER WE HAVE BEEN REPORTING ON Nov 2 2006 08:27
1 NEW! » Jeannine !!!...Fampridine-SR: WONDERFUL TRIAL RESULTS ON NEW DRUG Nov 2 2006 08:29
2 NEW! » queen_racewife PRESS RELEASE ON NEW DRUG: MBP8298 [TRIALS ARE VERY GOOD OUT OF THE US!!!] Nov 2 2006 08:35
1 NEW! » Mary and Robert GREAT STORY OF PERSEVERANCE Nov 2 2006 10:40
1 NEW! » Jeannine Study sheds light on myelination Nov 3 2006 07:04
1 NEW! » Jeannine FDA Approvals: Interferon-beta-1b (Betaseron) for Use in Early Multiple Sclerosis Nov 3 2006 18:13
1 NEW! » "Gamma Julie" 'miracle drug' is supposedly no good Nov 4 2006 02:01
2 NEW! » Roseanne ENVIRONMENT CAUSE OF WOMEN'S HIGHER RISK OF MS? Nov 4 2006 09:05
1 NEW! » Jeannine cladrabine Nov 4 2006 14:09
2 NEW! » Jeannine MS Society's 'Shining Star Nov 4 2006 14:30
1 NEW! » Jeannine NEW DRUG IN PIPELINE: MBP8298 Nov 4 2006 14:33
3 NEW! » David UK - EXPERTS believe they have discovered a protein which could help create new MS treatments Nov 4 2006 18:14
1 NEW! » Jeannine WONDERFUL STORY OF PERSEVERANCE IN THIS SUNDAY'S NYC MARATHON Nov 5 2006 12:08
1 NEW! » ~Ãngël~™ NPR AUDIO: Studies have found that a six-month Iyengar yoga program helped people with MS comba Nov 5 2006 17:35
2 NEW! » Jeannine "advances on the horizon..." Nov 6 2006 09:12
1 NEW! » Jeannine GREAT ADVICE FOR CAREGIVERS - stan Nov 6 2006 09:28
2 NEW! » Darth Woky ™ (UPDATE ON THIS STORY IS AB0VE) CHURCHILL DOWNS PERSEVERANCE Nov 7 2006 01:22
2 NEW! » "Gamma Julie" Award given to Scott Johnson, President and Founder of the Myelin Repair Foundation Nov 7 2006 04:46
2 NEW! » queen_racewife INTERESTING IMPLANT STUDY....update Nov 8 2006 03:38
1 NEW! » David (READ THE GREAT COMMENTS) TOVAXIN...NEW MS DRUG IN PIPELINE STARTS DOSING Nov 9 2006 22:56
2 NEW! » Lora GOOD INTERVIEW WITH AUTHOR OF NEW BOOK: ABOUT HER MS Nov 10 2006 13:39
2 NEW! » Mary and Robert Man says tai chi gave him second chance at life. Nov 10 2006 17:20
3 NEW! » Jeannine oral Trimesta (estriol)...A NEW MS DRUG IN THE PIPELINE!!!!! [UPDATE] Nov 10 2006 18:54
1 NEW! » Jeannine STORY OF 37-YEAR OLDS PERSEVERANCE Nov 10 2006 19:00
1 NEW! » Jeannine NEW BROCHURE: Volunteering for a Clinical Trial: Your Guide to Participating in a Trial Nov 10 2006 19:01
1 NEW! » Jeannine ECCO Shoes Plans to Donates $2 Per Pair of Shoes Sold to MS [good idea for US] Nov 10 2006 19:08
1 NEW! » Jeannine 58% of long-term care claimants are younger than 65 and the top five claims causes are MS, Canc Nov 10 2006 19:09
3 NEW! » Jeannine "Advances on the horizon in treating and curing MS" Nov 10 2006 19:15
1 NEW! » Jeannine A medical marijuana ballot in South Dakota Today Nov 10 2006 19:17
1 NEW! » Jeannine study identifies how treatment can limit impact of T-cells in autoimmune diseases Nov 10 2006 19:19
1 NEW! » Jeannine MS fundraising luncheon in Ne Jersey Nov 10 2006 19:19
1 NEW! » Jeannine Treatment of neuropsychiatric conditions associated with MS Nov 10 2006 19:21
1 NEW! » Jeannine BREEDERS CUP WIN! McLaughlin on his battle with MS (THE STORY ON THIS FROM LAST WEEK IS BELOW) Nov 10 2006 19:23
1 NEW! » Jeannine PERSEVERANCE: PAT KINSLEY GIVE BACK TO KIDS Nov 10 2006 19:27
1 NEW! » Jeannine GREAT AND IMPORTANT STORY ABOUT DOGS AS HELPERS FOR MS PATIENTS - stan Nov 10 2006 19:28
2 NEW! » Jeannine FDA APPROVAL: BETASERON UPDATE Nov 10 2006 19:30
2 NEW! » Jeannine ELK HUNTING & MS STORY Nov 10 2006 19:32
2 NEW! » Jeannine B12 and MS: UK MS SOCIETY EDITORIAL Nov 10 2006 19:33
3 NEW! » Mary and Robert Help fight multiple sclerosis with me - The Bakersfield Voice Nov 11 2006 02:06
2 NEW! » Mary and Robert {PERSEVERANCE}.....Cheri Piekarski's job is a labor of love Nov 11 2006 13:41
1 NEW! » Jeannine MARY MOLDS' MS DOESN'T STOP HER FROM HELPING OTHERS Nov 12 2006 08:05
3 NEW! » ♥Debbie♥ GOOD WHEELCHAIR NEWS: Battle over Payments Cuts by CMS is being won!!!! Nov 13 2006 08:24
3 NEW! » David "I believe that a person who can't read in our society is more handicapped than I am," Merens s Nov 13 2006 20:35
2 NEW! » Key two-headed snake Nov 13 2006 20:42
2 NEW! » MRSMUSTAINE NEW PATENTS FOR MS MED Nov 14 2006 02:08
1 NEW! » "Gamma Julie" Cannabis Study in news this AM Nov 15 2006 01:39
1 NEW! » "Gamma Julie" memory study Nov 15 2006 01:52
3 NEW! » "Gamma Julie" "Research Highlights" from the New York City Chapter of the National Multiple Sclerosis Society Nov 15 2006 01:59
1 NEW! » "Gamma Julie" GREAT ARTICLE...THINGS ABOUT RICHARD PRYOR & HIS DAUGHTER RAIN THAT HAVE NEVER BEEN TOLD!-stan Nov 15 2006 02:17
1 NEW! » "Gamma Julie" GETTING TOUGH ON MEDICINAL POT SELLERS Nov 15 2006 02:29
1 NEW! » queen_racewife SAMANTHA..PERSEVERANCE AND KINDNESS AT 15 YEARS OLD...."SHE IS MY REAL HERO"-stan Nov 15 2006 17:28
2 NEW! » queen_racewife BNC105: PRESS RELEASE ON THIS NEW DRUG IN PIPLINE Nov 15 2006 17:42
4 NEW! » queen_racewife STEM CELL STORY FROM THE UK Nov 15 2006 17:47
1 NEW! » David "laughing and intractable hiccups can occur early in MS" [study] Nov 16 2006 20:02
4 NEW! » David New Wave Of HOPE- Support Group Aims To Aid MS Patients Nov 17 2006 20:25
2 NEW! » David Amy Clawson: Country music artist Nov 17 2006 20:32
1 NEW! » David TYSABRI: Natalizumab Alters T Cell Ratio in MS Patients (Reuters Health) Nov 19 2006 10:09
2 NEW! » Alpha [GREAT READ] Geographical disparity of Diseases Nov 19 2006 18:55
1 NEW! » Jenn MBP8298: NEW DRUG IN PIPELINE Nov 19 2006 20:13
4 NEW! » Jenn ANOTHER CRAZY STORY FROM THE UK: "FREEZE TREATMENT FOR MS"  Nov 19 2006 20:24
1 NEW! » Tim Foolery There are a lot of new things in Krystal Hexamer's life: Research Promises New Treatment for MS Nov 20 2006 07:38
4 NEW! » Stacey OUR FRIEND LARRY NEEDS YOUR HELP: BOTH HE AND HIS MOM HAVE MS Nov 24 2006 07:56
3 NEW! » Shell THIS IS WHY I LOVE MySpace...AND MY MySpace FRIENDS - stan Nov 24 2006 11:36
1 NEW! » Mary and Robert Wheelchair bowlers still rolling Nov 18 2006 16:53
1 NEW! » David THIS POST CAME FROM OUR CORRESPONDENT ANNE: A SIMPLE TEST FOR MS Nov 19 2006 10:27
1 NEW! » Darth Woky ™ CLEVELAND CLINIC TIPS ON: STRESS AND MS Nov 20 2006 01:35
3 NEW! » ♥Debbie♥ "FAMOUS PATIENTS AND THE LESSONS THEY TEACH"...THE NEW YORK TIMES Nov 20 2006 05:11
4 NEW! » Tim Foolery Stem cells might cause brain tumors Nov 20 2006 07:22
1 NEW! » WaterDragon {READ THIS!!!-stan} DRUG COMBO SHOWS SHOCKING REVERSAL OF MS SYMPTOMS Nov 21 2006 04:36
1 NEW! » WaterDragon "What if we could actually reverse the damage that MS causes, restoring function..." Nov 21 2006 05:10
1 NEW! » Jeannine Stada said it is no longer to pursue its Interferon-beta project to treat MS Nov 21 2006 07:28
4 NEW! » Shell Clinical Trial Design Nov 22 2006 07:48
4 NEW! » Alpha STUDY FINISHED RE: people's concern about a perceived high rate of MS in Illinois cities Nov 22 2006 11:20
5 NEW! » David New Patent for diagnosing MS Nov 22 2006 13:17
1 NEW! » Roseanne GREAT EXPLANATION OF STEM CELLS AND THEIR POSSIBLE USE IN MS Nov 23 2006 07:37
2 NEW! » Alpha PERSONAL STORY OF THANKSGIVING Nov 23 2006 20:52
3 NEW! » Alpha SOUTH FLORIDA - National MS Health Expo Is November 19th Nov 24 2006 17:06
4 NEW! » Jeannine YOUR COMMENTS HAVE HELPED "FOOL ON THE HILL"...stan Nov 24 2006 19:00
3 NEW! » "Gamma Julie" {first time i've seen a charity benefit solely for low income ms patients-stan} Nov 25 2006 07:08
5 NEW! » Mary and Robert Multiple Sclerosis Society Alert re: funding Nov 25 2006 23:44
3 NEW! » Mary and Robert DACLIZUMAB FOR MS Nov 25 2006 23:46
4 NEW! » queen_racewife GOOD STORY - University of Rochester presses quest for stem cell breakthrough Nov 26 2006 10:50
5 NEW! » Alpha [WOW!!! READ THIS!!-stan] High-tech device helps a martial artist learn how to walk again Nov 26 2006 16:18
2 NEW! » Kendra OUR FRIEND KENDRA NEEDS OUR WISHES OF GOOD LUCK! HER SURGERY IS APPROACHING - stan Nov 27 2006 08:17
5 NEW! » Alpha Results of study on prevalence of MS in Lewistown to be presented Nov 28 2006 08:36
2 NEW! » ♥Debbie♥ "Do you believe in miracles? " By Linda Beck Nov 28 2006 10:02
1 NEW! » ♥Debbie♥ OUR FRIEND AND "STAR COMMENTATOR" KEY HAS GOOD NEWS Nov 28 2006 10:06
3 NEW! » ♥Debbie♥ THIS IS GREAT: FREE BOOKLET FROM THE UK Nov 28 2006 10:14
1 NEW! » ~♥sweet caroline♥~ OUR FRIEND DEBBIE NEEDS A HUG! SHE HAS A MESSAGE FOR EVERYONE Nov 28 2006 21:01
1 NEW! » Francine MS Holiday Gift Guide Nov 29 2006 08:07
8 NEW! » David "Glatiramer acetate therapy for multiple sclerosis" Nov 29 2006 19:30
1 NEW! » David DARTH WOKY: ONE OF MY BEST FRIENDS NEEDS YOUR ADVICE Dec 2 2006 12:38
3 NEW! » ♥Debbie♥ [update-18 comments] JENNIFER NEEDS SUPPORT: "MY LEGS ARE STIFF & LIFELESS" Dec 4 2006 08:14
2 NEW! » Anne SAD STORY FROM TODAYS HEADLINES Dec 5 2006 05:06
4 NEW! » Anne MELISSA NEEDS SUPPORT Dec 5 2006 05:32
2 NEW! » Kendra NO MERCURY RISK IN AMALGAM FILLINGS Dec 5 2006 08:16
2 NEW! » queen_racewife KIDS: "Why are our children's bodies attacking them? Dec 6 2006 02:55
4 NEW! » queen_racewife PERSEVERANCE: GREAT STORY Dec 6 2006 03:07
1 NEW! » queen_racewife HIGH INCIDENCE OF MS IN ILLINOIS TOWN PUZZLES RESEARCHERS Dec 6 2006 03:23
5 NEW! » queen_racewife PERSEVERANCE: GREAT RADIO INTERVIEW Dec 6 2006 03:35
2 NEW! » Shell PERSEVERANCE...Susan Greenop"s personal story Dec 6 2006 04:49
7 NEW! » Alpha STEM CELL STUDY Dec 6 2006 09:32
3 NEW! » (¯`•´¯)Starr(¯`•´¯) ARTISTS FOR MS Dec 6 2006 09:53
8 NEW! » Mich/Neurotrash'd TERI GARR Dec 7 2006 10:18
1 NEW! » Sean GREAT DISCOVERY AT STANFORD MED SCHOOL: Molecule Linked to Autoimmune Disease Relapses Found Dec 8 2006 15:54
2 NEW! » Mary and Robert GIVE CONGRATS TO TIM FOOLERY FOR GETTING A RAISE! Dec 8 2006 19:12
8 NEW! » David Prescription for the Soul Dec 8 2006 21:07
7 NEW! » Alpha GREAT NEW DRUG: Fampridine-SR Dec 9 2006 12:05
7 NEW! » (¯`•´¯)Starr(¯`•´¯) DISABLED STILL FACE OBSTACLES Dec 9 2006 14:31
5 NEW! » Rev UPDATE ON POT IN CANDY BARS FROM YESTERDAY Dec 10 2006 10:57
4 NEW! » ~Ãngël~™ UPDATE: 36 COMMENTS- ADD YOUR STORY & SHARE YOUR ADVICE: MS IS INTERFERING IN ANGEL'S LOVE LIFE Dec 10 2006 11:16
1 NEW! » Wendy SENATE PASSES GREAT NEW BILL FOR MS Dec 11 2006 08:04
5 NEW! » Tim Foolery "Activists are convinced that electrical pollution is making us sick" Dec 11 2006 09:31
6 NEW! » Tim Foolery GREAT STORY OF PERSEVERANCE FROM TODAY'S HEADLINES Dec 11 2006 09:32
1 NEW! » Tim Foolery CONGRATS TO LORA: SHE'S ALMOST DONE WITH LAW SCHOOL Dec 11 2006 09:33
6 NEW! » Tim Foolery A happy fundraising story - stan Dec 11 2006 14:29
2 NEW! » Jenn CONGRATS TO JENN: "I found out last Monday that hubby and I are expecting .2" Dec 11 2006 18:50
7 NEW! » Yvonne UPDATE ON YESTERDAYS TYSABRI STORY: "1000 MS PATIENTS REFUSED TYSABRI: IT COSTS TOO MUCH! Dec 12 2006 06:54
3 NEW! » Renee JILL'S BDAY IS TODAY...PLUS CONGRATS TO HER ON GRAD SCHOOL!! - stan Dec 13 2006 09:43
1 NEW! » WaterDragon 2 IMPORTANT NEW STUDIES ON GRAY MATTER DAMAGE IN MS Dec 14 2006 04:50
6 NEW! » Alpha MS FAMILY BATTLES LYME DISEASE Dec 14 2006 12:14
1 NEW! » Patti (aka Thelma) UPDATE ON MY POST FROM DECEMBER 4TH: "SIF IS GETTING CHEMO TOMORROW" Dec 14 2006 23:18
4 NEW! » Jeannine TYSABRI: RICH WANTS TO TAKE IT ...BUT HAS A QUESTION Dec 15 2006 07:02
5 NEW! » ~Ãngël~™ GREAT STORY ON NEW JERSEY BIKE TEAM Dec 15 2006 09:44
3 NEW! » ~♥sweet caroline♥~ SUPPORT TEAM ALERT: ANGEL HAS HELPED MANY OTHERS-NOW SHE NEEDS OUR SUPPORT - stan Dec 15 2006 16:08
3 NEW! » CARRIE AMAZING NEWS! CONGRATS TO EVERYONE WHO HAS BEEN MAKING COMMENTS! LOOK AT THIS INFO: Dec 15 2006 20:55
7 NEW! » David CONTROVERSIAL CLINIC SHUT DOWN Dec 15 2006 21:40
7 NEW! » Mary and Robert SAD STORY ABOUT JAZZ SINGER Dec 16 2006 14:58
2 NEW! » David "1000 PATIENTS IN THE UK TO BE DENIED TYSABRI: NOT COST EFFECTIVE" Dec 17 2006 12:25
1 NEW! » David BILLY TALLENT: one of my fav bands [my favorite is Hatebreed] - stan Dec 17 2006 13:37
5 NEW! » Jeannine A MESSAGE FROM ONE OF OUR SUPPORT ANGELS: ALPHA...WHO IS STRANDED IN SEATTLE! -stan Dec 18 2006 14:37
4 NEW! » Jeannine TYSABRI FOR CROHN'S DISEASE TOO!!!! Dec 18 2006 14:40
1 NEW! » Jeannine GREAT NEWS ON NEW MS DRUG FOR MS FATIGUE: MCT-125 Dec 18 2006 14:40
5 NEW! » Jeannine GIVE SPHILLY CONGRATS ON GETTING APPROVED FOR A GRANT Dec 18 2006 14:42
6 NEW! » Jeannine "HAPPY NEWS" FROM OUR SUPPORT ANGEL ANNE - stan Dec 18 2006 14:44
2 NEW! » Jeannine SUPPORT GROUP ALERT: I HAVE RECEIVED MANY EMAILS THIS WEEK FROM OUR FRIENDS WHO ARE SAD Dec 18 2006 14:46
3 NEW! » WaterDragon SUPPORT ALERT: "i have been just feeling like why me why did i have to have ms!" - TERI Dec 18 2006 16:57
4 NEW! » SPhilly SUPPORT ALERT: GIVE RainMaker A PAT ON THE BACK FOR STARTING HIS MS TREATMENT - stan Dec 18 2006 22:30
2 NEW! » Darth Woky ™ CONGRATS TO OUR ANGELS OF SUPPORT: YOUR ADVICE HELPED Holy Crip Dec 19 2006 01:32
4 NEW! » <3i data-blogger-escaped--="" data-blogger-escaped-09:57="" data-blogger-escaped-19="" data-blogger-escaped-2006="" data-blogger-escaped-at="" data-blogger-escaped-br="" data-blogger-escaped-coming="" data-blogger-escaped-dec="" data-blogger-escaped-drug="" data-blogger-escaped-glass="" data-blogger-escaped-great="" data-blogger-escaped-looking="" data-blogger-escaped-m="" data-blogger-escaped-new="" data-blogger-escaped-oral="" data-blogger-escaped-soon...hopefully="" data-blogger-escaped-stan="" data-blogger-escaped-the="" data-blogger-escaped-through="" data-blogger-escaped-you="">1 NEW! » (¯`•´¯)Starr(¯`•´¯) 1,039 FRIENDS VISITED OUR BLOG YESTERDAY & READ YOUR 125 COMMENTS!!!!!!!!!!! - stan  Dec 19 2006 10:15
4 NEW! » (¯`•´¯)Starr(¯`•´¯) TERI & ALPHA THINK THIS STORY WILL HELP EXPLAIN MS TO YOUR FAMILY: IT'S ALSO ON TYSABRI - stan Dec 19 2006 10:20
1 NEW! » Melissa NEW PAIN DRUG APPROVED FOR MS...IN EUROPE...WHICH MEANS IT WILL HOPEFULLY BE HERE SOON - stan Dec 19 2006 15:10
4 NEW! » Kim SUPPORT ALERT: BOTH SUSAN AND I NEED HELP! - stan Dec 19 2006 19:33
9 NEW! » Jeannine HAPPY HOLIDAY STORY IN TODAY' NEWS -stan Dec 20 2006 09:55
2 NEW! » Jeannine GIVE CHRIS...OUR NEWSEST ANGEL OF SUPPORT A HUG - stan Dec 20 2006 10:05
4 NEW! » Jeannine POSSIBLE NEW MS TREATMENT: SOY!!!!!!!!!!!!!!!! Dec 20 2006 10:27
5 NEW! » Jeannine INTERESTING STUDY ON RURAL VS URBAN USE OF DOCTORS IN MS PATIENTS Dec 20 2006 10:30
4 NEW! » Jeannine DIABETES BREATHROUGH - RELATIONSHIP TO MS? SEE MY POST ABOVE FROM VIVIAN Dec 20 2006 10:34
1 NEW! » Jeannine AN INTERESTING EMAIL ON DIABETES CURE AND I'S RELATION TO MS Dec 20 2006 10:35
7 NEW! » David THIS STORY IS BETTER THAN THE TRASH FICTION BOOKS I LOVE TO READ - stan Dec 20 2006 20:21
6 NEW! » David NEW MS DRUG UPDATE IN THE NEWS: CHR-1103 Dec 20 2006 20:23
4 NEW! » David UPDATE: FDA ADVISORY (WARNING) 2 Rituxan deaths: of Tysabri type..rare brain infection Dec 20 2006 20:30
7 NEW! » There Can Only Be One Me SUPPORT ALERT FOR FRANCINE - SHE HAS HELPED MANY FRIENDS - NOW SHE NEEDS HUGS! - stan Dec 21 2006 06:58
2 NEW! » Jeannine COGNITIVE TRAINING HELPS SENIORS" [STUDY] MAYBE IT WILL HELP MS TOO??? Dec 21 2006 06:59
1 NEW! » Miss Kitty MY MESSAGE TO OUR ANGELS OF SUPPORT- RE: YOUR 2 HOLIDAY GIFTS FROM ME + HELP 4 FRIENDS -stan Dec 21 2006 11:10
7 NEW! » :Vitamin DEE: STORY ON NEW MS DRUG IN THE PIPELINE: NEUROVAX Dec 21 2006 21:31
3 NEW! » queen_racewife READ 42 COMMENTS-MARIES IMPORTANT UPDATE ON HER Dec 22 2006 05:43
2 NEW! » (¯`•´¯)Starr(¯`•´¯) DEBBIE'S CHRISTMAS MESSAGE TO OUR Angels of Support Dec 22 2006 10:03
7 NEW! » (¯`•´¯)Starr(¯`•´¯) GREAT STORY OF A MED STUDENT'S PERSEVERANCE IN TODAYS HEADLINE NEWS - stan Dec 22 2006 10:20
7 NEW! » Anne ANOTHER SUCCESS FOR OUR Angel of Support KELLI'S VIDEO - stan Dec 22 2006 16:55
1 NEW! » Patti (aka Thelma) KISOR...OUR NEWEST ANGEL..HAS A REBIF TIP...ON GIVING YOURSELF A SHOT -stan Dec 22 2006 23:40
6 NEW! » WaterDragon SUPPORT ALERT QUESTION: "what have you heard about mono and ms? - shane Dec 24 2006 07:22
4 NEW! » David A GREAT STORY FROM MED STUDENT SOURCE: "New MS Therapies in Clinical Trials" Dec 24 2006 09:46
7 NEW! » David PERSEVERANCE IN TODAY'S NEWS Dec 24 2006 09:54
6 NEW! » David Romney has said he would end to his political career for his wife, who has MS. Dec 24 2006 10:00
1 NEW! » Luis TYSABRI SUPPORT ALERT: "Please help me Stan!" - JAMIE Dec 25 2006 06:29
4 NEW! » Lisa NEW STUDY ON MS & PREGNANCY Dec 25 2006 12:51
1 NEW! » Chanfb915 High Levels of Vitamin D In the Body May Decrease the Risk of MS: HARVARD PRESS RELEASE Dec 25 2006 18:29
3 NEW! » Mary and Robert ADD YOUR "HAPPY &/or FUNNY STORY" TO THE 31 BELOW: I'M GOING TO PUT THEM IN A SLIDESHOW - stan Dec 27 2006 00:46
1 NEW! » Mary and Robert SUPPORT ALERT UPDATE - 18 COMMENTS: "I am still trying to accept everything (dx Aug 2006)" Dec 27 2006 01:27
2 NEW! » Mary and Robert NEW PHOTOS-CONGRATS TO RENEE: "he popped the big question-he's seen me at my worse with my MS" Dec 27 2006 01:54
2 NEW! » Mary and Robert WELCOME sorormp3: OUR NEWEST Angel...A SUPER Stay-Home Mom and Retired Teacher Dec 27 2006 01:56
2 NEW! » Mary and Robert SUPPORT ALERT: "I'M DEPRESSED: Does anyone know anything about using chemo for MS?" - Valyum Dec 27 2006 01:59
1 NEW! » Mary and Robert OUR 17 YEAR OLD ANGEL ROSE GOT DIAMOND EARRINGS FOR XMAS: NICE BOYFRIEND! - stan Dec 27 2006 02:00
3 NEW! » Mary and Robert "I GOT A JOB OFFER STAN" - YVONNE Dec 27 2006 02:01
5 NEW! » Mary and Robert "a relationship suddenly breaking up. This happened last week-two days before my birthday." Dec 27 2006 02:12
8 NEW! » Mary and Robert "The greatest thing happened to me this past week at work!!!" - PATRICIA Dec 27 2006 02:15
1 NEW! » Mary and Robert "I wonder how I am going to be brave enough to self administer these injections? Dec 27 2006 02:24
4 NEW! » queen_racewife SUPPORT ALERT: "friends & family seem to be "backing off"-not sure how to "deal" with me & MS" Dec 27 2006 03:40
8 NEW! » queen_racewife WELCOME OUR NEWEST SUPPORT ANGEL: AMY Dec 27 2006 03:43
2 NEW! » queen_racewife SUPPORT ALERT: "i pray that i don't have a replapse while with family" - DIERDRE Dec 27 2006 04:03
4 NEW! » queen_racewife GREAT LONG STORY ON MY MAIN MS NEWS SITE - stan [too long 4 this blog] Dec 27 2006 04:05
5 NEW! » queen_racewife LADOSTIGIL (an Alzheimer's drug) for treating MS Dec 27 2006 04:17
3 NEW! » Gypsy Queen GOOD STORY ON EXERCISE FROM TODAY'S NEWS - stan Dec 27 2006 05:34
3 NEW! » Beth NATALIE'S PERSEVERANCE!!! YOUR COMMENTS OF SUPPORT HELPED NATALIE - stan Dec 27 2006 10:44
3 NEW! » David SUPPORT ALERT: "I HAD A MRI..IT SHOWED 1 NEW LESION FOR A TOTAL OF 10" - SUSAN Dec 27 2006 21:23
4 NEW! » David THIS IS A "INDEX OF STORIES" SLIDESHOW THAT IS UNDER CONSTUCTION: CAN U READ THE HEADLINES? Dec 27 2006 21:34
2 NEW! » Anne SUPPORT ALERT: My doctor says I may have MS & Fibromyalgia-does anyone else have both of these? Dec 28 2006 01:09
4 NEW! » HOOLIE 5 NEW TATS TODAY: "TATOOS AGAINST MS" Many have told me tatoos help them deal with MS Dec 28 2006 07:27
4 NEW! » Donna Mojo-"Athos" HAS A MOOD TIP: "I HAVE DAYS WHEN I'M SO LONELY THAT I SIT IN MY ROOM AND CRY" Dec 28 2006 10:25
1 NEW! » "Gamma Julie" SUPPORT ALERT FOR GENEISIS & HER "MS NIGHTS! DO U HAVE THE SAME PROBLEM? TELL US! - stan Dec 28 2006 02:58
1 NEW! » "Gamma Julie" COPAXONE SUPPORT ALERT: JULIE'S HUSBAND IS GETTING LUMPS LIKE A MARBLE @ THE INJECTION SITE!?? Dec 28 2006 03:12
2 NEW! » queen_racewife TYSABRI: HARVARD MED SCHOOL'S TOP 10 STORIES OF 2006 Dec 28 2006 05:28
10 NEW! » ~Ãngël~™ SUPPORT ALERT FOR SANDRA: "I AM SO STRESSED WITH THIS & DON'T KNOW WHAT TO DO" Dec 28 2006 07:49
10 NEW! » Jeannine 1,066 VISITORS & 152 COMMENTS ON OUR BLOG YESTERDAY - stan Dec 28 2006 08:02
6 NEW! » Key MS family's appearance on the ABC television show "Extreme Makeover: Home Edition" Dec 28 2006 12:13
15 NEW! » Katrina (great update: note from Kendra) SUPPORT ALERT: KENDRA NEEDS HUGS AND A NEW DOC!!! -stan Dec 28 2006 12:36
5 NEW! » Yvonne SUPPORT ALERT: "SINCE MY DX MY SEX LIFE HAS BEEN SHIT" DARTH WOKIE Dec 28 2006 12:46
3 NEW! » queen_racewife For kids, MS itself just half the battle: Correctly diagnosing disease can be tricky Dec 28 2006 12:59
15 NEW! » WaterDragon FATIGUE RELIEF: THIS IS ONE OF THE MOST IMPT POSTS I'VE MADE OUT OF 596 I'VE POSTED - stan Dec 28 2006 13:10
4 NEW! » Alpha [4 NEW ANGELS THIS AM] THESE 26 FRIENDS HAVE JOINED OUR 91 ANGELS OF SUPPORT THIS WEEK Dec 28 2006 14:13
16 NEW! » D SUPPORT ALERT FOR OUR NEWEST ANGEL-NANCY WHO HAS "WEIGHT GAIN OF 50 POUNDS" = stan Dec 28 2006 14:19
1 NEW! » Alpha SUPPORT ALERT: CANCER HASN'T STOPPED BRIAN'S WANTING TO BE AN "ANGEL OF SUPPORT" [HUGS! PLEASE]

Labels: Avonex, Betaseron, Rebif, Rituxan, Tysabri

BURLINGTON, Mass., April 8, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive multiple sclerosis (PP-MS), surveyed U.S. neurologists would be willing to accept a certain level of risk for a therapy with proven efficacy on disability progression, likely owing to the absence of approved therapies for this indication.

Read more »

Labels: Gilenya, Primary-Progressive PPMS

The United States Supreme Court has granted certiorari in a patent case that could extend the market exclusivity of a top-selling multiple sclerosis drug, forcing generics to wait to enter the market.
Read more »

SHE'S BEEN ON IT FOR A YEAR & ITS HELPING HER WIN HER FIGHT AGAINST MULTIPLE SCLEROSIS!

Labels: Gilenya

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

The risk is "substantially higher than previously reported and [is] often the sole factor prompting patients to switch to another MS [disease-modifying therapy].
Click here to read more

• "It takes about 2 x as long for someone with MS to absorb and process information as someone who does not have MS: Back to School With MS? Here's How"
• Multiple Sclerosis Treatment Options: Breakdown of Associated Risks
• Study: Tysabri (Natalizumab) to fingolimod washout in patients at risk of PMLFingolimod, Tysabri
• Neil Cavuto on Feeling Moved to Tell His Viewers: ‘It’s Not Me, It’s The Multiple Sclerosis’
• Merck KGaA shores up Rebif defenses to fend off new MS rivalsRebif
• Play the MS Matching Game: brain games can help exercise your mind
• Survey showed strong uptake of the new 40-milligram, thrice-weekly version of Teva's Copaxone, estimating that about 40% of MSers will have switched to it after two yearsCopaxone
• New warning suggested for Ambien...the same sleeping pill that landed a Kennedy before a jury: says patients shouldn't drive for 8 hours after they take meds like Ambien
• $15 Million awarded to former Newark teacher with MS who says district retaliated against her
• A Glittering Rock Reunion of 14,300 Fans Becomes the Best of Get-Well Gifts for Guitarist Ronnie Lane
• Study: 2014 Multiple Sclerosis Therapeutic Update, UCSF MS Department of Neurology, San Francisco, CA
• Study: High prevalence and no latitude gradient of multiple sclerosis in Norway
• Study: Supervised exercise training has substantial benefits for MSers, yet 80% of those with MS do not meet recommended levels of moderate-to-vigorous physical activity (MVPA)
• "British Health Minister Edwin Poots witnessed first-hand how oxygen therapy can help MSers enjoy a better quality of life"
• Illinois lottery game fund multiple sclerosis research
• BREAKING NEWS! WARNING: Pfizer Issues Nationwide Recall of Antidepressant Effexor
• For Runner With M.S., No Pain While Racing, No Feeling at the Finish (New York Times)
• A MSer's story of how she & her Neuro both had problems with Anthem BlueCross getting her MS treatment refilled:10 BEST
• Doctors’ #1 Source for Healthcare Information: Wikipedia
• Merck KGaA shores up Rebif defenses to fend off new MS rivals
• Novartis, Sanofi, Biogen tout new MS drug researchAubagio, Copaxone, Gilenya, Tysabri
• My recent struggles made me realize, you only live life one time
• "Innate Immunotherapeutics delivered results from animal studies which further support its novel MIS416 therapy as a candidate to treat Secondary Progressive Multiple "Sclerosis (SPMS)
• Oregon Health & Science University today announced the creation of the OHSU Center for Embryonic Cell and Gene Therapy, led by Shoukhrat Mitalipov, Ph.D., a world-renowned leader in embryonic stem cell and gene therapy research
• Study: Neglecting data from individuals with MS who exhibit head movement during functional magnetic resonance imaging (fMRI) scanning may bias sampling away from individuals with lower cognitive ability
• Study: MiR-126: a novel route for Tysabri (natalizumab) action?Tysabri
• "Dr. Monson has developed a validated method for pre-testing people living with MS to determine if they are a carrier of a unique antibody gene that leads to the disease, thus mitigating the long-standing challenge of diagnosis"
• MS trial to explore vitamin D links
• Study: Oxygen Cost of Walking in Persons with Multiple Sclerosis: Disability Matters, but Why?
• A SAD BUT IMPORTANT LESSON FOR ALL MSers: "Inquest hears how MSer dropped match or cigarette onto her bed that engulfed her in flames and burnt down her home
• This MSer believes marijuana helped put his MS in remission: soon however, Davidson will be forced to destroy the medicine he credits with saving his life
• Biogen Idec finished 2013 on a high note, with its highly touted oral multiple sclerosis drug Tecfidera producing nearly $400 million in sales during the fourth
• Study Findings from Biogen Idec, Inc. Provide New Insights into Multiple Sclerosis
• Slightest change makes myelin come unglued: One common characteristic of diseased myelin is swelling due to MS
• OMG of the week: Doctors flee homes after declaring strike
• What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?
• How Inactivity Change MSer's Brains
• One-liners may hint at feelings about health care
• RUNNING HELPS ME MANAGE MY MS: Jeanine Parson
• I'm a mother of 3 young children and here's my horror story of my MS & the new health care law
• TAKEDA ADMITS TO IMPROPERLY MARKETING BLOCKBUSTER DRUG a AFTER DOCTOR POINTS OUT DATA IN AD DIDNT MATCH RESULTS OF CLINICAL STUDY
• Study: “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis
• Clues To Causes Of Nerve Cell Degeneration in MS Provided By Spasticity Gene Finding
• Minn. physicians ponder medical pot: Is marijuana an effective treatment for pain, illness and disease?
• Study: MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge
• Variables associated with patient activation in persons with multiple sclerosis
• What Vitamin D Dosage Do I need? How Much Sun Do I Need?
• Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
• Express Scripts stops covering older, commonly used treatments such as Bayer's multiple sclerosis drug Betaseron on clinical, cost-effectiveness grounds
• Study: Antiviral drug Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS
• Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis
• Study: Constraint-induced movement therapy increased neuroplasticity in MS patients according to MRI findings, whereas massage, yoga, and other "complementary/alternative medicine" treatments did not.
• Arshiya’s special talent: I used to jump all the way down the steps in Hodge Lee in one leap. I felt like Superman, or rather, Superwoman. That was before I got MS
• TEVA'S COPAXONE PATENT IS UP AND ITS DESPERATE TO KEEP PATIENTS & INSURERS
• DOES THIS NEW STUDY MEAN ANYTHING FOR MS PATIENTS?: "Medical Marijuana: Studies Find No Benefit for RA: Rheumatologists should not currently be recommending the use of medical marijuana to their patients for relief of chronic pain, researchers stated
• 4 Things All Doctors Need To Know About Health IT Security
• Video: THE SCANDAL THAT ROCKED THE PATIENT SAFETY MOVEMENT BREAK...
• CAN CAFFEINE HELP AN MSers MEMORY: Caffeine’s little memory jolt garners a lot of excitement
• Air Force Academy's future rests in Lt. Gen. Michelle Johnson steady hands: the institution's first female superintendent, has been tearing down barriers all her life including MS
• Senate Passes Casey MS Resolution Ahead of Multiple Sclerosis Awareness Week
• "MS doesn't define us - it's just there"
• 7 women are suing Doctor & health network for medical negligence, claiming the doctor misdiagnosed them with multiple sclerosis
• "My 1st experience as an immunologist diagnosed with MS" by Griselda Zuccarino-Catina, PH.D.
• DOCTORS BEDSIDE MANNER: written by a doctor
• Immunophenotyping Separates MS Subtypes by Neuroinflammation
• What's new in the fight against MS? USA Today
• Another big beast joins the MS Drug fray: ofatumumab phase 2 trial results
• MSnewsChanel.com.com
• Study may provide future insights into causes and mechanisms of MS
• 30% of the 16,651 people who died of an opioid overdose also had taken a benzodiazepine
• Working as a full time police officer & living with MS
• Here's 5 ways to help ease the pain of winter months
• Obamacare Hikes Cost to Patients of Specialty Drugs for MS
• The battle of a 6th grader recently diagnosed with MS
• Study: Stethoscopes carry more bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), than a physician’s hand
• Merck's Rebif is a 3rd major MS drug to be discovered in Israel: The Israeli Connection
• Kristen discovers running as way to combat her MS
• Cara Therapeutics has exciting new MS drugs in their pipeline
• Study: See One, Do One: Watching Action Boosts Brain Volume, Ability
• Study: Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection
• We've posted 314 Studies & Stories for you so far this week
• FOR DOCTORS ONLY: 15 Smartphone Apps to Improve Your PracticeDocs Only
• WEEKEND LOL REPORT: Medical School Limiting the Number of Creepy Applicants to Cut Down on Creepy Doctors
• Video: 'Dallas Buyers Club' connects with MSers
• FOR DOCTORS ONLY: Study Companion: Mastering Clinical Concepts in MS Management

Labels: Aubagio, Betaseron, Gilenya, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:

www.MSnewsChannel.com


ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES?

ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity
ECTRIMS Congress 2013: African Americans With MS at More Visual Risk

ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS

Halting MS to Be Focus at ECTRIMS Congress 2013

ECTRIMS Congress 2013:  New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS

ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -

ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems

ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate)  20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress

ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE

ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
 
ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM"

ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)

ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?

Labels: Aubagio, ECTRIMS CONGRESS 2013, Gilenya, TECFIDERA, Tysabri, Vitamin D

I Listened to ME!  Was I right...was I wrong!

Living with MS 37 years, having 3 Neuro's, diagnosed in a time there were no ABC drugs, infusions, pills...nothing!  Knowing so many personally with MS and watching them take the new drugs with only disease progression.

A firm believer in listening to my own body, while understanding all of what my doc is saying.  I will never know if I was right or wrong.  34 years I lived without a drug, I lived with severe symptoms, but able to live what was my new norm.

3 years ago, my Neuro changed, I, now had a very aggressive doc who started from scratch, an MRI etc.  Before, no lesions active, now facing 3 new lesions all active.  Scared, fear, staying rational all encompassed me.  What in the hell am I going to do now?  The question was let the disease progress or slow it down, if the drug of choice worked for me...

My Neuro told my husband and I, “There was no waiting now, MS will at some point rear it's ugly head.”  I could only take Copaxone, due to complications with other drugs.
I am in my 3rd year of daily injections, thankfully no complications.  I did have an over night exacerbation in 2012, due to extreme stress, because of personal loss.

My MRI, now shows an old lesion in my spine totally disappeared and 3 others not active.  My Neuro entered on last visit calling me her “SUPER RESPONDER!”  I was responding to Copaxone like no other patient.  At first I didn't hear what she said, because of her excitement in her voice, finally feeling something good for a welcome change.

I cannot go back in time, but only move forward, I will always be in the biggest fight of my life living with MS.  I now have a great respect, along with hatred of this disease, like never before in my life. This disease needs to be stopped!  Is enough being done?  Don't ask me, I'm trying to survive the beast!  Just one of many!  And those that will hear, “You have MS!”

Never wish a second, an hour, a day away and NEVER take anything for granted!  For Multiple Sclerosis has NO SYMPATHY for anyone, no matter what age.

The Best!
Dee Ryden

For 3/29/14

Click here to read

Read more »

STOCK DOWN 8%: WHAT'S BEHIND TEVA'S MASSIVE PLUNGE?

Read more »

Labels: TECFIDERA, Video

Click here to read

Labels: Avonex, Copaxone, Rebif, TECFIDERA, Tysabri

3/13/12
1. Personal history
Timothy L. Vollmer, M.D. CURRICULUM VITAE
University of Colorado School of Medicine 12631 East 17th Avenue, Mail Stop B185 Aurora, Colorado 80045


2. Education
 University of Wyoming, Laramie, WY (B.A. Zoology with Highest Honors), 1973-1977
 Stanford University School of Medicine, Stanford, CA (M.D.), 1977-1982
 Intern in Internal Medicine, Yale New Haven Hospital, New Haven CT, 1982-1983
 Resident in Neurology, Stanford University Hospital, Stanford, CA, 1983-1985
 Post Doctoral Fellow in Neuroimmunology, University Hospital, Stanford, CA, 1985-1986
 Chief Resident in Neurology, Stanford University Hospital, Stanford, CA, 1986-1987
 ACPE Physician Executive Course I, 1995
 Yale School of Medicine and Yale School of Business Physician Executive Course, 1997
3. Academic Appointments
 Assistant Professor, Department of Neurology, Yale University School of Medicine, New Haven, CT, 1987—1993
 Medical Director, Rocky Mountain Multiple Sclerosis Center, Swedish Medical Center, Englewood, CO, 1993—1995
 Associate Clinical Professor, Department of Neurology, University of Colorado, Denver, CO, 1993—1995
 Associate Professor, Department of Neurology, Yale University School of Medicine, New Haven, CT, 1996—2002
 Vice Chairman-Clinical Affairs, Department of Neurology, Yale University , New Haven, CT, 1996—2002
 Director, Yale Multiple Sclerosis Research Center, New Haven, CT, 1996—2002
 Associate Director for Clinical Studies, Center of Excellence on Restoration of Function in
Spinal Cord Injury and Multiple Sclerosis, U.S. Dept. of Veterans Affairs, Division of Rehabilitation Research and Development, Connecticut VA Healthcare System, West Haven, CT, 1996—2002
 Chair, Division of Neurology, Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center, Phoenix, AZ August, 2002—March, 2007
 Associate Residency Program Director, Barrow Neurological Institute at St. Joseph Hospital and Medical Center, Phoenix, AS, January, 2004—August, 2008
 Director, Neuroimmunology Program, Barrow Neurological Institute at St. Joseph Hospital and Medical Center, Phoenix, AZ, August, 2002—August, 2008
1

3/13/12
4.
5.
 Van Denburgh Professor of Neurology, Barrow Neurological Institute at St. Joseph Hospital and Medical Center, Phoenix, AZ, March 2002—August, 2008
 Co-Director, Rocky Mountain MS Center at Anschutz Medical Campus 2008—Present
 Medical Director, Rocky Mountain MS Center 2008—Present
 Professor of Neurology, University of Colorado Denver 2008—Present
 Director, Neurosciences Clinical Research, University of Colorado Denver 2010—Present
Other Professional Positions
 Nancy Davis Center Without Walls Investigator, 1994—2002
 Director, NARCOMS Project for Consortium of MS Centers 1996—2011
Honors, Recognitions and Awards
 Voted in top quartile of attending physicians by medical students at University of Colorado School of medicine for academic year 2010-2011
 Accelerated Cure Project for Multiple Sclerosis PHYSICIAN OF DISTINCTION AWARD, 2011
 Best Doctors, Top 1% of neurologists ranked nationally by US News & World Report and Castle Connolly Medical, Ltd. 2011
 Fellow, American Academy of Neurology 2009
 University of Colorado Department of Neurology Teaching Award 2009
 Diplomat, American Academy of Neurology, Section of Multiple Sclerosis 2001
 Best Doctors in American 2003—2004
 National Multiple Sclerosis Society Volunteer Hall of Fame
 Who’s Who in North America
 Who’s Who in Science
 Who’s Who in Medicine
 Best Doctors in New York, Castle Connolly Medical LTD
 2000 Outstanding Scientists of the 21st Century-First Edition (Melrose Press, LTD., Ely, Cams.
UK)
 American Neurology Association Fellow
 Scholars Program (Appointment (Stanford University)
 Dean’s Fellowship (Stanford University)
 Alpha Epsilon Delta
 Omicron Delta Kappa
 Phi Beta Kappa
 Phi Kappa Phi
 University of Wyoming Honors Scholarship
Memberships in Professional Organizations
 Colorado Society of Clinical Neurologists
 Arizona Medical Association 2003-2004
 American Academy of Neurology
 American Association of Immunology
 American Neurological Association
 American Society of Experimental NeuroTherapeutics
2
6.
3/13/12
 Consortium of Multiple Sclerosis Centers
 International Society for Neuro Immunology
 Society for Neuroscience
 Royal Academy of Physicians
7. Major committee and service responsibilities
 University of Colorado School of Medicine Admissions Committee, 2010--
 Advisory Committee, 109MS201, Biogen Idec
 NARCOMS Team member
 NARCOMS Steering Committee (?—2010)
 Consortium of Multiple Sclerosis Centers (CMSC Board of Governors – member
 Clinical Advisory Committee—National Multiple Sclerosis Society, Local Chapter
 Clinical Advisory Committee—National Multiple Sclerosis Society, Member
 Steering Committee, FTY720 Studies, Novartis
 National Professional Advisory Committee-National MS Society
 Yale Medical Student Preclinical Curriculum Committee Chairman, 1992-1993
 Yale School of Medicine Senior Clinician Committee, Member, 1993/01996-2002
 Yale Clinical Research Policies Review Committee 2000
 Councilor, MS Section, American Academy of Neurology, 2001
 Data Safety and Monitoring Committee, ARA V A, Adventis, Chairman, 2001-2002
 Yale Dept of Neurology Clilnical Management Team, Chairman, 1996-2002
 Yale Medical Student Admission Committee, Member, 1998-2002
 Yale Faculty Practice Plan Contracting Committee, Member, 1999-2002
 Yale Provost’s Standing Committee on Conflict of Interest, Member, 2000-2002
 Yale School of Medicine Credentialing committee, Member, 1999-2002
 Clinical Review Committee, CHAPS and CHAMPIONS Study, 1998-2002
 Yale School of Medicine Strategic Planning Committee, Member, 1996
8. Licensure and board certification
 State of Colorado licensure
 Board certified, American Board of Psychiatry and Neurology, 1991
9. Review and referee work
 Editor, Multiple Sclerosis Quarterly Report (MSQR); 1999—2005
 Co-Editor, Multiple Sclerosis Quarterly Report (MSQR); January, 2005—Present
 Editorial Board, European Journal of Neurology; 2010--present
10. Invited extramural lectures, presentations and visiting professorships

 
“New Treatment Strategies in MS” presentation at New Perspectives in Multiple Sclerosis: Epidemiology, Pathology, Imaging and Treatment Strategies CME symposia, sponsored by State University of New York, University at Buffalo. New Orleans, LA., Sept. 11, 2010 Johns Hopkins University CME videotaped presentation sponsored by MedicalLogix: “Advances in MS: Emerging Strategies for Neuroprotection and Neuroregeneration” Grand Rounds presentation to University of California San Diego School of Medicine August, 12, 2011
3
3/13/12
10.1. Conferences organized and/or chaired
1. Yale Clinical Neuroimmunology Conference, Yale School of Medicine, Chair, 1993
2. International Committee on Databases in MS, Inaugural Meeting, Venice, Italy, Chair, 1999
3. International Committee on Databases in MS, Second Annual Meeting, Fort Worth, Texas, Chair, 2001
4. Yale Neuroimmunology Conference, Yale School of Medicine, Chair, 2001
5. Yale International Conference on Schwann Cell Transplantation in MS, Yale School of Medicine,
2001
6. 29th Annual Barrow Neurological Institute Neurology Symposium, Barrow Neurological Institute,
Committee Member, 2003
7. 30th Annual Barrow Neurological Institute Neurology Symposium, Barrow Neurological Institute,
Committee Member, 2004
8. 31st Annual Barrow Neurological Institute Neurology Symposium, Barrow Neurological Institute,
Committee Member, 2005
9. 32nd Annual Barrow Neurological Institute Neurology Symposium, Barrow Neurological Institute,
Committee Member, 2006
10. 33rd Annual Barrow Neurological Institute Neurology Symposium, Barrow Neurological Institute,
Committee Member, 2007
11. Exercise as a Prescriptive Therapy in MS: What We Know and What We Need to Know. A Consensus
Conference, organizer and presenter. Denver, Colorado October 2-3, 2010
11. Teaching record
 Grand Rounds presentation-University of Colorado Department of Neurology
 December 11, 2009
 December 12, 2010: “Immunotherapies of MS: New Opportunities and New Risks”
 December 7, 2011: “Is Multiple Sclerosis a Disease of Oligodendrocytes, Neurons or
Astrocytes? Why Does it Matter?”
 Invited Grand Rounds presentations
 August 12, 2011, University of California San Diego
 Resident Education presentations
 June 3, 2009. Goals of Immunotherapy in MS Using FDA Approved DMANS;
 June, 2010 Our Evolving Understanding of MS, Implications for Future Therapies;  October 6, 2010. Case presentations
 December 8, 2010: Immunological therapy in MS
 Student Teaching
 October 7, 2009 4th year student lecture, Path 8001, CNS Analysis, University of Colorado School of Medicine
 October 11, 2011 4th year student lecture, University of Colorado School of Medicine Clinical Laboratory Medicine, Pathology 8001, CSF Analysis.
 January 31, 2012 Neuroscience Graduate Education Lecture, University of Colorado School of Medicine
4
Chair,
3/13/12
 Attending Neurologist at University Hospital
 March 1—March 15, 2009  June 1—June 15, 2009
 Oct 4—Oct 7, 2010
 Oct 18, 2010
 Oct. 19—Oct. 31, 2010
 January 1—January 15, 2011
 Neuro Service/Stroke Call August 18, 2011, September 14, 2011, October 31, 2011,
December 21, 2011
 Mentees/trainees
 Jonathan Goldstein, M.D., Associate Professor of Neurology, Yale School of Medicine
 Jana Preiningerova, M.D. formerly Assistant Professor of Neurology, Yale School of
Medicine. Currently residing in Eastern Europe
 Robert Bomprezzi, M.D., PhD. Assistant Professor of Neurology, Barrow
Neurological Institute
 Wenhua Piao, PhD
 Wei Liu, PhD. Faculty, Albert Einstein College of Medicine
 Mrinalini Kala, PhD. Faculty, University of California San Francisco
 Youn Jee, M.D., PhD. Assistant Professor, Cheju National University, School of
Medicine, Korea
 3rd year medical students at University of Colorado 2010--2011:
Daren Eblovi, Brent Fowler, Julian Maendel, Yihan Lin, Samuel Mast, Matthew Percy,
Amy Reppert, Benjamin Snyder, Tobin Strom, Tyra Thorstad, Asa Ware.
 Residents, University of Colorado School of Medicine, 2010-2011:
Charles Braun, Haley Burke, Emily Gertsch, Takamasa Higashimori, Kimberly Horiuchi, Drew Kern, Angel Pulido, Peter Bergman, Emily Lampe, Eryn Lonnquist, Danielle McDermott, Marius Birlea, Adam Graham, Aaron Haug, Wesley Reynolds, Katie Polovitz, Teri Schreiner, 2010--2011
 David Case, Mentee Resident University of Colorado School of Medicine 2008—2009; 2009—2010; 2010—2011
 Preceptor for Kiara Foltyn 1st year medical student, University of Colorado School of Medicine, 2010
 Matthew West, M.D., Neuro-Immunology Fellow, 2010--2011
 Teri Schreiner, M.D., Neuro-Immunology Fellow, 2011—2012
 Preceptor for Jacob Pellinen, 2nd year medical student, University of Colorado School
of Medicine 2011-2012
 Preceptor for Jeremy Hua 1st year medical student, University of Colorado School of
Medicine, 2011--
5
3/13/12
1.
2. 3. 4. 5. 6. 7. 8. 9.
10.
1.
2.
3. 4
12. Grant support—Current as Primary Investigator
MS-LAQ-302E, TEVA Neuroscience (extension) Vollmer (PI) 12/01/2009-11/30/2012
This project is an extension of the MS-LAQ-302 (BRAVO) study to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis
101-MS-402 TYGRIS: TYSABRI, Biogen Idec, Inc. Vollmer (PI) 11/13/2008-11/12/2011
This project assesses the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in patients with MS treated with TYSABRI® (natalizumab).
CAMMS32409, Genzyme Vollmer (PI 02/07/2011- 02/06/2014 This project is an extension protocol for Multiple Sclerosis patients who participated in Genzyme- Sponsored studies of Alemtuzumab, such as CAMMS32400507
ONO-4641 POU006, Ono Pharmaceutical Co Vollmer (PI) 01/2010-04/30/2013 This project is a flexible-dose titration study of the safety and tolerability of ONO-4641 in patients with a relapsing form of multiple sclerosis
ONO-4641POU007 (Extension) Ono Pharmaceutical Vollmer (PI) 03/01/2011-2/28/2014 To evaluate continuing safety and efficacy of ONO-4641 in patients who have completed an initial 26- week study (ONO-4641POU006)
101JC401, Biogen Idec Vollmer (PI) 05/01/2010-04/30/2013 JVC Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-1
101JC402, Biogen Idec Vollmer (PI) 07/01/2010-06/30/2013 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2
109MS201 Biogen Idec Vollmer (PI) 06/01/2010-05/31-2015 To evaluate the safety and tolerability of BG00012 administered in combination with IFNβ or GA in subjects with remitting-relapsing multiple sclerosis. EXPLORE
Rocky Mountain Network for Neuroscience Clinical Studies (RMNNCS).
NIH/NINDS 1U10NS077277-01 Vollmer (PI) 9/30/11-9/30/18
10-1143, Gateway II Teva Vollmer (PI) 10/1/2011-3-31-2014 Randomized study comparing rituximab induction therapy followed by glatiramer acetate to glairamer acetate monotherapy in RRMS
12.1Grant support—Past
Duloxetine in patients with central neuropathic pain Vollmer (PI) 10/31/2008-10/30/2011
Lilly Research Laboratories
This project assesses the efficacy of duloxetine 60 mg once daily (QD) compared with placebo on the reduction of pain severity as measured by the weekly mean of the daily 24-hour average pain scores in patients with central neuropathic pain in MS.
A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β-1a (Avonex®) administered IM once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase, Novartis , (Sub Investigator)
A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis, BioMS Technology Corp., (Sub Investigator)
Improved Diagnosis of Multiple Sclerosis Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction TM Test: MS Template Development Study. Orasi (Sub Investigator)
6
3/13/12
5 A 14 week Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispiridine 50 mgm, 100 mg. and 200 mg in Patients With Multiple Sclerosis, Sanofi Aventis (Principal Investigator)
6 A Phase 1 Open-Label, Flexible-Dose Titration Study of the Safety and Tolerability of ONO-4641 in Patients with a Relapsing Form of Multiple Sclerosis, Ono Pharma USA. ONO 4641 (Principal Investigator)
7 A Study with IPX056 in Subjects with Spasticity Associated with Multiple Sclerosis (Principal Investigator)
8 A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study on Add-on Cladribine Tablet Therapy with Rebif® New Formulation in Multiple Sclerosis Subjects with Active Disease, Serono International S.A., Serono, Inc., (Principal Investigator)
9. A Phase 2 Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab® in Patients with Active, Relapsing Forms of Multiple Sclerosis, PDL BioPharma, Inc., (Principal Investigator)
10. Biomarkers in Multiple Sclerosis, Division of Intramural Research (DIR), NIH/NINDS, (Principal Investigator)
11. Online Validation of Multiple Sclerosis International Quality of Life (MuSI-QoL) Questionnaire, Serono/Pfizer, (Principal Investigator)
12. A Prospective Study of Quality of Life and Cost of Disease in a Selected Group of MS Patients Treated with Novantrone, Serono International S.A., Serono, Inc. (Principal Investigator)
13. Development of Peripheral Blood Diagnostics and Biomarkers for Alzheimer's Disease, Arizona Biomedical Research Commission (ABRC), (Subinvestigator)
14. Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis, Acorda Therapeutics, Inc. (Principal Investigator)
15. Open-Label Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple-Sclerosis, Acorda Therapeutics, Inc. (Principal Investigator)
16. A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients with Multiple Sclerosis (Principal Investigator)
17. A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera®/Rituxan®) in Adults with Primary Progressive Multiple Sclerosis, Genentech, Inc., (Principal Investigator)
18. A Phase II, Proof-of-Concept, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera®/Rituxan®) in Adults with Relapsing-Remitting Multiple Sclerosis, Genentech, Inc., (Principal Investigator)
19. A Cross Sectional Study to Evaluate the Persistence of Immunological Effects of Glatiramer Acetate (Copaxone®) in Patients with Relapsing Forms of Multiple Sclerosis , Barrow Neurological Foundation, (Principal Investigator)
20. Specimen and Data Collection and Archiving for Immunological Investigations Aiming to Understand the Immunological Mechanism of Multiple Sclerosis (MS) and Identify New Targets For Immune Therapies for Multiple Sclerosis and Other Autoimmune Diseases and Neuroinflammatory Disorders, Barrow Neurological Foundation (Principal Investigator)
21. Gene Expression Assay of Patients with Multiple Sclerosis and Other Neurological Diseases, On and Off Immunological Therapy, Compared to Healthy Controls, Barrow Neurological Foundation/TGen, (Principal Investigator)
22. A Genomics Study of Blood Markers of Disease Activity in Multiple Sclerosis (Co-Principal Investigator)
23. Phase I Trial of Immunotherapy with BHT-3009 Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis (Lead Investigator)
7
3/13/12
24. International, randomized, multicenter, Phase IIIb study in patients with relapsing-remitting multiple- sclerosis comparing over a treatment period of 104 weeks: 1) Double-blinded safety, tolerability, and efficacy of Betaseron/Betaferon 250 ug (8MIU) and Betaseron/Betaferon 500 ug (16 MIU), both give subcutaneously every other day, and 2) Rater-blinded safety, tolerability, and efficacy of Betaseron/Betaferon s.c. every other day with Copaxone 20 mg s.c. once daily. (Principal Investigator)
25. A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250mg Subcutaneously Every Other Day with Avonex® 30mg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex®. (Principal Investigator)
26. A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects with Relapsing- Remitting Multiple Sclerosis" (Principal Investigator)
27. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788- in Patients with Relapsing Multiple Sclerosis (Principal Investigator)
27. Multiple Sclerosis Instrument Quality of Life Project (MuSI-QoL) (Principal Investigator)
28. Phase IV, Multicenter, Open Label, Randomized Study Of Rebif 44 Mcg Administered Three Times
Per Week By Subcutaneous Injection Compared With Copaxone 20 Mg Administered Daily By Subcutaneous Injection In The Treatment Of Relapsing Remitting Multiple Sclerosis (Principal Investigator)
29. A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis Teva Neuroscience,( Lead Investigator)
30. Immunological Studies for a Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone) Preceding Treatment with Glatiramer Acetate (Copaxone) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis Teva Neuroscience,(Co-Principal Investigator)
31. Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response, Biogen Idec, (Principal Investigator)
32. A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis, NIAID/ITN, (Principal Investigator)
33. A Multi-Center, Two Arm, Open Label Extension Study (to protocol NC_100) to Evaluate the Long- Term Safety and Efficacy of Short-Term Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment With Glatiramer Acetate (Compaxone®) vs. Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis, Teva Neuroscience (Lead Investigator)
34. A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Dose Subcutaneously Administration of a Human Monoclonal Antibody to IL-12 (CNTO 1275) in Patients with Relapsing Forms of Multiple Sclerosis (Principal Investigator)
35. A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase
36. Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis
37. Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg B.I.D.) in Subjects with Multiple Sclerosis
38. A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients with Multiple Sclerosis
39. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients with Relapsing Multiple Sclerosis
8
3/13/12
40. A Randomised, Double-blind, Placebo-controlled, Parallel group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Three Months Administration of SB-683699 (150-1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis
41. An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing- remitting multiple sclerosis following treatment with firategrast
42. A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX® Compared with AVONEX® in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough Disease on AVONEX® Monotherapy
43. Phase I Trial of Immunotherapy with BHT-3009 Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis
44. An Open-Label, Multicenter Study to Assess the Safety of AVP-923 Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (Principal Investigator)
45. An open-label and drug interaction study of natalizumab in combination with interferon-beta (Avonex®) in patients with multiple sclerosis.
46. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis (Principal Investigator)
47. A Phase II, Randomized, Double-Blind, Placebo Controlled Study To Evaluate The Preliminary Efficacy, Pharmacokinetics and Immunogenicity Of BMS-188667 Administered To Subjects With Relapsing-Remitting Multiple Sclerosis (Principal Investigator)
48. A 10 Year Open-Label Extension Study To Evaluate The Safety Of Copaxone And To Monitor The Neurologic Course of Disease In Multiple Sclerosis Patients Treated With Copaxone (Principal Investigator)
49. A Two-Arm, Cross-Over Design, Two Dose, Dose Escalation, Safety and Tolerability Study of Oral Interferon Beta-1a (Avonex) in Multiple Sclerosis (Lead Investigator)
50. An Open-Label, Randomized, Multi-Center, Comparative, Parallel Group Study Of Rebif 44 Mcg Administered Once Per Week By Intramuscular Injection In The Treatment Of Relapsing -- Remitting Multiple Sclerosis (Principal Investigator)
51. An Open-Label, Randomized, Multi-Center, Comparative Parallel Group Study of Rebif Compared with Avonex in Relapsing-Remitting Multiple Sclerosis (Principal Investigator)
52. Characterization of Human Schwann Cell Lines – In Vitro Safety and Viability Studies (Co- Investigator)
53. Phase I Trial of Autologous Schwann Cell Transplantation in MS as a Myelin Repair Strategy in MS Patients (Lead Investigator)
54. An Open-Label, Single-Arm, Cross-over, Frequent MRI Study of Simvastatin as a Therapy for Multiple Sclerosis (Lead Investigator)
55. A Multi-National, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Glatiramer Acetate for Injection in Primary Progressive Multiple Sclerosis Patients (Principal Investigator)
56. Randomized, Double Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography (IGIV-C), 10% Treatment on Relapsed Rater in Patients with Multiple Sclerosis (Principal Investigator)
57. An Open-Label Safety Extension Study Of Avonex (Interferon Beta-1a Treatment In Subjects Who Completed Biogen Studies C95-812, C96-823, Or C97-830 (Principal Investigator)
58. A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy of Avonex in the Treatment of Secondary Progressive Multiple Sclerosis (Principal Investigator)
59. An Open-Label, Randomized, Multi-Center, Comparative, Parallel Group Study of Rebif 44 mcg Administered Three Times Per Week by Subcutaneous Injection, Compared with Avonex 30 mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-Remitting Multiple Sclerosis (Principal Investigator)
9
3/13/12
60. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Safety, Tolerability And Dose Evaluation Study of Intravenous Antegren (Natalizumab) At Two Dose Levels Using Magnetic Resonance Imaging In Subjects With Multiple Sclerosis (Principal Investigator)
61. A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Tolerability, And Safety Of Two Doses (5 Mg And 50 Mg) Of Glatiramer Acetate Orally Administered In Relapsing Remitting Multiple Sclerosis Patient (Principal Investigator)
62. A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Comparing The Safety, Tolerance And Efficacy Of RTX (Resiniferatoxin) Topical Solution In Patients With Detrusor Hyperreflexia (Investigator)
63. Performance Scale V alidation Study (Principal Investigator)
64. Symptom Inventory Validation Study (Principal Investigator)
65. The Effects of Betaseron on Quality of Life in MS -A Q- TWiST Evaluation (Principal Investigator)
66. A Double-Blind, Placebo-Controlled, Multi-center Study of Oral Myelin (Myloral) in the Treatment of
Early Relapsing- Remitting MS (Principal Investigator)
67. A Phase II, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two
DosesofBetaseroninPatientswithSecondaryProgressiveMultipleSclerosis(Principal Investigator)
68. A Multi-Center, Open-Label, Long-term Study to Evaluate the Safety of Tizanidine for Spasticity Due
to MS (Principal Investigator)
69. A Double Blind, Placebo Controlled Trial of Total Lymphoidal Irradiation in Multiple Sclerosis
(Principal Investigator)
70. A Double Blind, Placebo Controlled Trial of Tizanidine as an Anti-Spastic Therapy in Multiple
Sclerosis (Principal Investigator)
71. A Double Blind, Placebo Controlled Phase II Trial of 4-AP in MS (Principal Investigator)
72. A Pharmacodynamic Study of Tizanidine in MS (Principal Investigator)
73. Open Trial of Tizanidine in Multiple Sclerosis (Principal Investigator)
74. A Double Blind, Placebo-Controlled, Dose-Determination, Safety, Tolerability and Efficacy Study of
Intravenous Antegren In Patients with Multiple Sclerosis During an Acute Exacerbation (Principal
Investigator)
75. A Phase II Study of Hu23F2G in Acute Exacerbations of Multiple Sclerosis (Principal Investigator)
76. An Open-Label Study to Assess the Long-Term Safety of Zanaflex (tizanidine HCL) in Patients Treated
with 28 to 36 mg/day (Principal Investigator)
77. An Open Label Dose Proportionality Study to Assess the Pharmacokinetics of Escalating Doses of
Fampridine (4-Aminopyridine) in Subjects with Multiple Sclerosis (Principal Investigator)
78. An Open-Label Protocol to Assess the Steady State Pharmacokinetics of orally Administered
Fampridine (4-Aminopyridine) in Subjects with Multiple Sclerosis (Principal Investigator)
79. An Open-Label, Safety and Pharmacokinetic Drug Interaction Study of Intravenous Antegren and
Intramuscular Interferon beta-1a in Subjects with Multiple Sclerosis (Principal Investigator)
80. The Prevalence of Neutralizing Antibodies in Patients Treated with Betaseron or Avonex (Principal
Investigator)
81. Factors Related to Non-Adherence to Treatment with Disease-Modifying Drugs in Multiple Sclerosis
(Co- Investigator)
82. A Double Blind, Placebo Controlled Multi-Center Trial of Copolymer-1 in Relapsing Multiple
Sclerosis (Principal Investigator)
83. Cost-Benefit And Cost-Effectiveness Analysis Of Interferon Beta-1a Therapies For Multiple Sclerosis
(Lead Investigator)
84. Randomized Multicenter Trial of Intravenous Natalizumab In Acute MS Relapses: Clinic and MRI
Effects (Lead Investigator)
85. CS 0777-A-U102, Daiichi Sankyo Pharma Development Vollmer (PI) This project assessed the
safety and tolerability of oral CS-0777 administered for 12 weeks in patients with MS.
86. Duloxetine in patients with central neuropathic pain. Lilly Research Laboratories Vollmer (PI)
This project assesses the efficacy of duloxetine 60 mg once daily (QD) compared with placebo on the
10
3/13/12
reduction of pain severity as measured by the weekly mean of the daily 24-hour average pain scores
in patients with central neuropathic pain in MS.
87. HP 184: Nerispiroline, Sanofi Aventis US, Inc. Vollmer (PI)
This project assesses the activity of nerispirdine in imporving the ability to walk in persons with MS.
88. Consortium of Multiple Sclerosis Centers, NARCOMS Vollmer (PI)
The project is directed toward continuing the NARCOMS registry for persons with MS.
89. IPX056-B09-01, Impax V ollmer (PI)
A study with IPX056 in subjects with spasticity associated with multiple sclerosis
90. MS-LAQ, TEVA Neuroscience (BRAVO) Vollmer (PI)
This project assesses the efficacy, safety, and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon β-1a (Avonex®) in a rater-blinded design and to perform a comparative benefit/risk assessment between oral laquinimod and injectable Interferon β-1a (Avonex®).
91. Disability-Specific Symptom Inventory Short Forms to Improve MS Outcome Assessment Vollmer (co-investigator)
Department of Defense, U.S. Army Medical Research Acquisition Activity (subcontract to DeltaQuest
Foundation, Inc)
92. ELND002-MS103, Elan Pharm V ollmer (PI)
To determine the safety and tolerability of ELND002 including the identification of dose-limiting
toxicity (ies) and determination of the maximum tolerated dose in patients with multiple sclerosis.
93. CAMMS32400507, Genzyme V ollmer (PI)
This project compares two annual cycles of IV low-and-high-dose Alemtuzumab to three-times weekly subcutaneous interferon beta 1a (Rebif) in patients with relapsing remitting multiple sclerosis
13. Bibliography—peer reviewed journal articles
1. Barbour RV DS, Vollmer TL, Harris JD. Pyrolysis of Utah tar sands - Products and Kinetics. Fuels. 1977;56:359-366.
2. Vollmer TL, Conley FK. Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells. Cancer Res. Sep 1984;44(9):3902-3906.
3. Vollmer TL, Waldor MK, Steinman L, Conley FK. Depletion of T-4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: a model of superinfection in AIDS. J Immunol. Jun 1 1987;138(11):3737-3741.
4. Redmond DE Jr SD, Naftolin F, Roth R, Bunney BS, Leranth C, Robbins R, Kier L, Vollmer TL, Levine RJ, Genel M, Zonana H. Ethics of Research Using Human Fedal Tissue. New England Journal of Medicine. 1989;321:1609.
5. Redmond DE, Jr., Leranth C, Spencer DD, Robbins R, Vollmer T, Kim JH, Roth RH, Dwork AJ, Naftolin F. Fetal neural graft survival. Lancet. Sep 29 1990;336(8718):820-822.
6. Vollmer TL, Brass LM, Waxman SG. Lhermitte's sign in a patient with herpes zoster. J Neurol Sci. Dec 1991;106(2):153-157.
7. Rice CL, Vollmer TL, Bigland-Ritchie B. Neuromuscular responses of patients with multiple sclerosis. Muscle Nerve. Oct 1992;15(10):1123-1132.
8. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. Nov 26 1992;327(22):1541-1548.
9. Goldstein JM, Azizi SA, Booss J, Vollmer TL. Human immunodeficiency virus-associated motor axonal polyradiculoneuropathy. Arch Neurol. Dec 1993;50(12):1316-1319.
10. Redmond DE, Jr., Robbins RJ, Naftolin F, Marek KL, Vollmer TL, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, et al. Cellular replacement of dopamine deficit in Parkinson's disease using
11
3/13/12
human fetal mesencephalic tissue: preliminary results in four patients. Res Publ Assoc Res Nerv Ment
Dis. 1993;71:325-359.
11. Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA. Idiopathic granulomatous angiitis of
the central nervous system. Diagnostic challenges. Arch Neurol. Sep 1993;50(9):925-930.
12. Goldstein JM, Waxman SG, Vollmer TL, Lang B, Johnston I, Newsom-Davis J. Subacute cerebellar
degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects. J Neurol Neurosurg Psychiatry. Sep 1994;57(9):1138-1139.
13. Miller A BD, Ritvo P, Stuart W, Vollmer T. The neurologist's perspective: what do we know and where do we go? Journal of Neurorehabilitation. 1994;8:105-111.
14. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD, Baumel B, Hsu CY, Murphy F, Reader AT, Schapiro RT, Sibley WA, Stazio A, Trotter JL, Vollmer TL, Walshe TM. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. Nov 1994;44(11 Suppl 9):S34-42; discussion S42-33.
15. Weinberg DA, Lesser RL, Vollmer TL. Ocular myasthenia: a protean disorder. Surv Ophthalmol. Nov- Dec 1994;39(3):169-210.
16. Coulthard-Morris L, Vollmer T. Multiple sclerosis fatigue: classification and treatmetn options. Multiple Sclerosis. 1995;2:2-6.
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer TL, Weiner LP, Wolinsky JS. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. Jul 1995;45(7):1268-1276.
18. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurol. Jul 1995;52(7):680-686.
19. Vollmer TL. A neurologist's perspective on enhanced MRI of multiple sclerosis. MRI Perspectives. 1995;2:1-3.
20. Vollmer TL, Gaiser C, Dell'Oca RL, Porteus M, Steinman L, Stevens DA. Coccidioidal antigen reactive CD4+ T-lymphocytes in the cerebrospinal fluid in coccidioides immitis meningitis. J Med Vet Mycol. Jan-Feb 1995;33(1):43-48.
21. Maravilla KR, Vollmer TL. The current view of MRI in multiple sclerosis. MRI Perspectives. 1996;3:1-3.
22. Vollmer T. Multiple sclerosis: new approaches to immunotherapy. The Neuroscientist. 1996;2:127- 136.
23. Cook SD, Devereux C, Troiano R, Wolansky L, Guarnaccia J, Haffty B, Bansil S, Goldstein J, Sheffet A, Zito G, Jotkowitz A, Boos J, Dowling P, Rohowsky-Kochan C, Volmer T. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. J Neurol Sci. Nov 25 1997;152(2):172-181.
24. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, O'Connor P, Cohen JA, Schapiro RT, Whitham R, Mass MK, Lindsey JW, Shellenberger K. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. Jun 1997;54(6):731-736.
25. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol. Dec 1997;54(12):1475-1480.
26. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. Mar 1998;50(3):701-708.
12
3/13/12
27. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. Jan 1 1999;52(1):63-70.
28. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. Mar 23 1999;52(5):1072-1074.
29. Vollmer TL NW, Stanton S, Hadjimichael O. The NARCOMS patient registry: a resource for investigators. International Journal of MS Care. 1999;1:12-15.
30. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group (including Vollmer TL). Mult Scler. Aug 2000;6(4):255-266.
31. Minagar A SW, Vollmer TL, Willmer-Hulme AJ, Koller M. Reduction of relapses in multiple sclerosis after anti-alpha4 integrin antibody (natalizumab). International Journal of MS Care. 2000;2(1):1-6.
32. Vollmer TL. Use of MRI technology in determining prognosis and tracking therapeutic benefit in multiple sclerosis. International Journal of MS Care. 2000;2(2).
33. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs. Oct 2001;33(5):231-239.
34. Kohama I, Lankford KL, Preiningerova J, White FA, Vollmer TL, Kocsis JD. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J Neurosci. Feb 1 2001;21(3):944-950.
35. Goodman AD BA, Cohen JA, Cross AH, Katz M, Rizzo MA, Vollmer TL. Placebo-controlled double- blinded dose ranging study of fampridine-SR in multiple sclerosis. Multiple Sclerosis Clinical and Laboratory Research. September 2002 2002;8(1:S97):308.
36. Markovic-Plese S PA, Cortez A, Vollmer TL. Therapeutic potential of statins in relapsing-remitting multiple sclerosis. Mutliple Sclerosis Clinical and Laboratory Research. September 2002 2002;8(1:S127):340.
37. Marrie R CJ, Hadjimichael O, Vollmer TL. Use of alternative providers in multiple sclerosis. Multiple Sclerosis Clinical and Laboratory Research. September, 2002 2002;8(1):63.
38. Preiningerova J DZ, Cannistraci C, Sun H, Vollmer TL. Computer assisted volumetric analysis of gadolinium enhancement in multiple sclerosis. Mutliple Sclerosis Clinical and Laboratory Research. September, 2002 2002;8(1:S97):245.
39. Rizzo M HO, Buenconsejo J, Preiningerova J, Vollmer TL. Spasticity in MS patients in the NARCOMS registry: prevalence, severity and treatmetn patterns using oral agens and/or intrathecal baclofen. Multiple Sclerosis Clinical and Laboratory Research. September, 2002 2002;8(1:S80):191.
40. Vollmer T. (Guest Editor) Introduction: A single topic issue on multiple sclerosis. J of Rehabil Res Dev. 2002;39(2).
41. Vollmer TL, Hadjimichael O, J. B. Quality of life and cost of illness in mitoxantrone treated multiple sclerosis patients. Multiple Sclerosis Clinical and Laboratory Research. September, 2002 2002;8(1:s78):185.
42. Vollmer TL, Preiningerova J, Markovic-Plese S, Rizzo M, Cutter G. A phase IIB study of oral interferon beta-1a at two doses in relapsing remitting multiple sclerosis using MRI, clinical and immunological measures. Multiple Sclerosis Clinical and Laboratory Research. September, 2002 2002;8(1:S71):163.
43. Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans. J Rehabil Res Dev. Mar-Apr 2002;39(2):163-174.
44. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs. Jun 2003;35(3):163-170.
45. Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler. Oct 2003;9(5):461-466.
13
3/13/12
46. The Transverse Myelitis Consortium Working Group (including Vollmer T). Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. Feb 25 2003;60(4):730-731; author reply 730-731.
47. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. Jun 2004;36(3):120-129.
48. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. Jun 8 2004;62(11):2038-2043.
49. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. Oct 2004;10(5):589-595.
50. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. May 15 2004;363(9421):1607-1608.
51. Vollmer TL SI. Author's reply for statins in multiple sclerosis. The Lancet. July 2004 2004;364:412- 413.
52. Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS. An open- label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler. Oct 2004;10(5):511-520.
53. Ding Z, Preiningerova J, Cannistraci CJ, Vollmer TL, Gore JC, Anderson AW. Quantification of multiple sclerosis lesion load and brain tissue volumetry using multiparameter MRI: methodology and reproducibility. Magn Reson Imaging. Apr 2005;23(3):445-452.
54. Hadjimichael O, Cutter G, Tyry T, Vollmer T. Are untreated MS patients representative of historical controls or what do they say about trial recruitment? Neurology. 2005;March 2005(Suppl 1):S36.005.
55. Khan M, Vollmer T, Singh A. Lovastatin augments the survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Mult Scler. September 2005 2005;11(Supplement 1):P212.
56. Liu R LA, Bai X, Jee Y, Price M. Campagnolo D, Christadoss P, Vollmer T, Van Kaer L, Shi F. Cooperation of iNKT cells and CD4+CD25+ treg cells in the prevention of autoimmune myasthenia. Neurology. 2006 March 14;66((5 Suppl 2)):A306.
57. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler. Feb 2005;11(1):33-40.
58. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: fatigue assessment. Mult Scler. Oct 2005;11(5):583-584.
59. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. Oct 11 2005;65(7):1066-1070.
60. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Vollmer T. Validation of the NARCOMS Registry: pain assessment. Mult Scler. Jun 2005;11(3):338-342.
61. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. Sep 2005;19(11):1407-1421.
62. Sheremata WA, Minagar A, Alexander JS, Vollmer T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs. 2005;19(11):909-922.
63. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol. Mar 1 2005;174(5):2696- 2701.
64. Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. Sep 2006;22(9):1671-1678.
65. Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol. May 1 2006;176(9):5247-5254.
14
3/13/12
66. Marrie R, Cutter G, Tyry T, Vollmer T, Campagnolo D. NARCOMS validation study. Neurology. 2006;66(5 Suppl 2):A226.
67. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. Apr 25 2006;66(8):1235-1240.
68. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. May 2006;59(5):780-787.
69. Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y, Smrtka J, Vollmer T, Singh I, Markovic-Plese S. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. Sep 2006;178(1-2):130- 139.
70. Tyor WR IS, Vollmer T, Key L, Corboy J, Markovic-Plese S, Preningerova J, Durkalski V, Rizzo M. The use of statins in multiple sclerosis. International Journal of MS Care. 2006;8:10-12.
71. Jee Y LR, Bai X, Campagnolo D, Shi F, Vollmer T. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int Immunol. 2006 April;18(4):537-544.
72. Vollmer T, LaPierre Y, Weiner L, Oger J, Bar-Or A, Arnold D, Campagnolo D, Barkas W, Antel J, Kachuck N. Garren H, Gianettttoni J, Steinman L, Valone F. Phase I/II trial of MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin for treatment of multiple sclerosis. Neurology. 2006 Mar 14;66((5 Suppl 2)):A306.
73. Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol. Dec 15 2005;175(12):7898-7904.
74. Paintlia A PM, Singh A, Vollmer T, Singh I. Combination therapy with Lovastatin and 5- aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside: approach for neuroprotection and inhibition of neurodegeneration in multiple sclerosis. Neurology. 2006 March 14;66((5 Suppl 2)):A303.
75. Coyle PK, Halper J, Johnson KP, Kalb R, Lublin F, Marrow T, Panitch H, Rabouls T, Vollmer T. Relapses matter: the costs & consequences of multiple sclerosis relapses. J Neurol Sci. May 15 2007;256 Suppl 1:S1-4.
76. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. Apr 2007;13(3):357-368.
77. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. Jan 2007;127(1-2):35-41.
78. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. Jul 2007;13(6):770-775.
79. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. Jun 5 2007;68(23):1971-1978.
80. Schwartz EI, Smilenov LB, Price MA, Osredkar T, Baker RA, Ghosh S, Shi FD, Vollmer TL, Lencinas A, Stearns DM, Gorospe M, Kruman, II. Cell cycle activation in postmitotic neurons is essential for DNA repair. Cell Cycle. Feb 1 2007;6(3):318-329.
81. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. May 15 2007;256 Suppl 1:S5-13.
82. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol. Oct 2008;255(10):1473-1478.
83. Bomprezzi R SM, Vollmer TL. Acute axonal polyneuropathy combined with acute disseminated encephalomyelitis: case report. Barrow Quarlery. 2008;24(2):21-23.
84. Devitt M, Foley FW, Miller RJ, Zemon V, Halper J, Campagnolo D, Vollmer T. Use of single screening question from NARCOMS to detect severe depression in multiple sclerosis. International Journal of MS Care. 2008;10(1):11-13.
15
3/13/12
85. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.
86. Hauser SL, Waubant E, Arnold DL, Vollmer TL, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. Feb 14 2008;358(7):676-688.
87. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. Sep 2008;255(9):1354-1360.
88. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. Sep 2008;14(8):1091-1098.
89. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Validation of the NARCOMS registry: depression assessment. International Journal of MS Care. 2008;10(3):84-84.
90. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. Jun 2008;14(5):663-670.
91. Zhao CB, Coons SW, Cui M, Shi FD, Vollmer TL, Ma CY, Kuniyoshi SM, Shi J. A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin. Biochem Biophys Res Commun. May 23 2008;370(1):16-21.
92. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler. Aug 2009;15(8):959-964.
93. Buchanan RJ, Chakravorty BJ, Tyry T, Hatcher W, Vollmer T. Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristics. NeuroRehabilitation. 2009;25(4):271-278.
94. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. Oct 2009;66(4):460-471.
95. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. Jan 2009;15(1):105-113.
96. Marrie RA CG, Tyry T, Campagnolo D, Vollmer T. Effect of physical comorbidities on risk of depression in multiple sclerosis. International Journal of MS Care. 2009;11(4):161-165.
97. Marrie RA, Cutter G, Tyry T, Vollmer T. Bladder care for veterans with MS differ by treatment location. International Journal of MS sCare. 2009;11:91-97.
98. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Smoking status over two years in patients with multiple sclerosis. Neuroepidemiology. 2009;32(1):72-79.
99. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology. Oct 27 2009;73(17):1394-1398.
100. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. Jan 13 2009;72(2):117-124.
101. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer, TL . The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler. Mar 2009;15(3):385-392.
102. Motl RW, Schwartz CE, Vollmer T. Continued validation of the Symptom Inventory in multiple sclerosis. J Neurol Sci. Oct 15 2009;285(1-2):134-136.
103. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. Feb 1 2009;182(3):1730-1739.
104. Tu JL, Zhao CB, Vollmer T, Coons S, Lin HJ, Marsh S, Treiman DM, Shi J. APOE 4 polymorphism
results in early cognitive deficits in an EAE model. Biochem Biophys Res Commun. Jul 10 2009;384(4):466-470.
16
3/13/12
105. Vollmer T, Blight AR, Henney HR, 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther. Oct 2009;31(10):2215-2223.
106. Vollmer T, Henney HR, 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin Ther. Oct 2009;31(10):2206-2214.
107. Buchanan RJ, Minden SL, Chakrovorty BJ, Hatcher W. Tyry T, Vollmer T. A pilot study of young adults with multiple sclerosis: Demographic, disease, treatment and psychosocial characteristics. Disabil Health J Oct: 3(4):262-70. Epub 2009 Nov 26.
108. Bandari DS, Vollmer TL, Khatri BO, Tyry T. Assessing quality of life in patiaents with multiple sclerosis. International Journal of MS Care. 2010;12(1):34-40.
109. Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. Aug 10 2010;75(6):568-570.
110. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate- treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. Jan 2010;221(1):136- 145.
111. Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. Sep 29 2010 124:2 135-41.
112. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. Mar 30 2010;74(13):1041-1047.
113. Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. Feb 2010;26(2):493-500.
114. Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology. Jan 5 2010;74 Suppl 1:S41-46.
115. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. Apr 2010;9(4):381-390.
116. Goodman AD, Brown TR, Edward KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR on behalf of the MSF204 Investigators (Vollmer TL). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol Oct 2010;68:494-502
117. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. Published online Oct 9 2010. Doi: 10.1136/jnnp.2010.214924.
118. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakrovorty BJ, Tyry T, Moreau RL, Huang C, Vollmer T. Comparisons of Latinos, African Americans and Caucasians with multiple sclerosis. Ethnicity and Disease 2010;20 autumn:451-457.
119. Marrie RA, Rudick R, Norwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010 74:13 1041- 7
120. Marrie RA, Horwitz R, Cutter G, Tyry T, Vollmer T. Smokers with MS are more likely to report comorbid autoimmune diseases. Neuroepidemiology 2011;36:85-90 (doi: 10.1159/000323948)
121. Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL. A review of cases of neuromyelitis optica. Neurologist 2011 March;17(2):98-104.
122. Vollmer T, Wynn D, Alam S, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double- blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relasping-remitting or secondary-progressive multiple sclersois. 2011 Multiple Sclerosis Journal February17(2) 181--191 .
17
3/13/12
123. Miravalle A, Hendin B, Vollmer TL, Mrinalini K. Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis. Clinical Medicine Insights: Therapeutics. 2011:3 151—158
124. Motl RW, McAuley E, Wynn D, Vollmer T. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. Am J. Phys. Med. Rehabil May 2011(90;5);372—379
125. Hao J, Campagnolo D. Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, VanKaer L, LaCava A, Shi FD. Interleukin-2/InterleukinL 2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Published online 18 MAR 2011 Annals of Neurology,
69: n/a. doi: 10. 1002/ana.22339
126. Schwartz CE, Sprangers MA, Oort FJ, Ahmed S, Bode R, Li Y, Vollmer T. Response shift in patients with multiple sclerosis: an application of three statistical techniques. Qual Life Res, 2011 20:10 1561- 72.
127. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Vollmer T. A pilot study of latinos with multiple sclerosis: demographic, disease, metnal health and psychosocial characteristics. Journal of Social Work in Disability & Rehabililtation, Nov 30, 2011, 10:4, 211-231
128. Shi J, Tu JL, Gale, SD, Baxter L, Vollmer TL, Campagnolo DI, Tyry TM, Zhuang Y, Kuniyoshi SM. APOE epsilon4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis. Cogn Behav Neurol 2011 24:3 128—33.
129. Bomprezzi, R, Schafer R, Reese V, Misra A, Vollmer TL, Kala M. Glatiramer acetate-specific antibody itres in patients with relapsing/remitting multiple sclerosis and in experimental autoimmunte encephalitis. Scan J. Immunol. 2011 74:3 219-26.
13.1 Bibliography-Peer Reviewed Publications—In press/accepted for publication
1. 2. 3. 4.
5. 6.
7. 8.
9.
Smith R, Trisolini M, Mauskopf J, Eckert B, Vollmer T. The side effects and mode of administration of disease-modifying therapies on EQ-5D index scores. 2009 Multiple Sclerosis (in press)
Kala M, Bomprezzi R, Schafer R, Resse V, Campagnolo D, Vollmer T. Glatiramer specific antibody titers do not correlate with clinical outcomes of multiple sclerosis. 2010 (accepted)
Smith KW, Trisolini M, Mauskopf J, Eckert B, Vollmer T. Impact of treatment burden associated with injected disease-modifying therapies on health utility in multiple sclerosis. 2010. (accepted) Yarden J. Schmidt H., Spector L, Fire E, Loud S, Dotan N, Venkatasan A, Frohman E, Sadiq S, Thrower B, Riskind P, Rackle MK, Vollmer TL, Kingel RP. gMS®ProEDSS blood tests based on anti-GAGA antibodies detects rapid relapsing remitting multiple sclerosis disability progression. 2010 (pending)
Moreau R, Salter AR, Tyry T, Marrie RA, Vollmer T, Cutter GR. Work absenteeism and mobility levels in people with multiple sclerosis. 2010 (pending)
Waubant E, Pelletier D, Mass M, Cohen J, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stuve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi P, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetski H, Ding L, Rosenberg E, ITN020AI Study Management team Spencer C, Zamvil SS. A randomized double-blind controlled study of Atorvastatin therapy in patients with clinically isolated syndrome: the STAyCIS study. (in progress)
Kala M, Miravalle A, Vollmer T. Recent advances in mechanism of action of glateramer acetate. 2011 Journal of Neuroimmunology (accepted-in press)
Schwartz CE, Bode RK, Vollmer TL. The symptom inventory disability-specific short forms for multiple sclerosis: Construct validity and responsiveness, and interpretation. Archives of Physical Medicine and Rehabilitation, 2012 (pending)
Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross AH, Bar-Or A, Vollmer TL, Racke MK, Stuve O, Schwid SR, Goodman AD, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C,
18
3/13/12
10.
11. 12.
13.
13.2 1. 2. 3.
4. 5. 6. 7.
8.
9. 10.
13.3. 1.
2.
Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS Study. Accepted for publication in Neurology 2011.
Campbell J, McQueen RB, Miravalle A, Corboy J, Vollmer T, Nair K. Comparative effectiveness of early natalizumab treatment in JCV negative relapsing-remitting MS. Submitted to Neurology Jan. 2012
Schwartz, CE, Snook, E, Quaranto B, Benedict RHB, Rapkin BD, Vollmer T. Cognitive reserve and appraisal in multiple sclerosis. MS and Related Disorders under review March, 2012
Moberly J, Vollmer T et. al Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients. Accepted for publication in J of Neuroimmunology, in press March, 2012
Schwartz CE, Bode RK, Vollmer T. The symptom inventory disability-specific short-forms for multiple sclerosis: Reliability and factor structure. Archivies of Physical Medicine and Rehabilitation, 2012 (in press)
Bibliography-- Book Chapters
Vollmer TL. Waxman SG. Multiple Sclerosis and Other Demyelinating Disorders. In Neurology. Ed. R. Rosenberg. Raven Press. 1991.
Vollmer TL. Waxman SG. Demyelinating Disorders of the Central Nervous System. In Neurologic Emergencies. Ed. WJ Weiner. JB Lippincott & Co. 1992.
Redmond DE. Robbins RJ. Raftolin F. Marek KL. Vollmer TL. Leranth C. Roth RH. Price LH. Gjedde A. Bunney BS. Sass KJ. Elsworth JD. Kier EL. Makuch R. Hoffer PB. Spencer DD. Cellular Replacement Strategy to Restore Dopamine Deficit In Parkinson's Disease Using Grafts of Fetal Mesencephalic Tissue: Preliminary Results In Four Patients. In Molecular and Cellular Approaches to the Treatment of Neurological Disease. Ed. S.G. Waxman. Raven Press. 1994.
Vollmer TL. Waxman SG. Demyelinating Disorders of the Central Nervous System. In Neurology. Ed. R. Rosenberg. Raven Press. 1997.
Vollmer TL P1-22 Multiple Sclerosis: The Disease and Its Diagnosis. In Multiple Sclerosis in Clinical Practice. Ed. S. van den Noort and N. Holland. Demos Medical Publishing. 1999.
Vollmer TL. Preiningerova J. Waxman SG. Multiple Sclerosis. In Encyclopedia of Life Sciences, http://www.els.net, London: Nature Publishing Group. 2002.
Okuda DT, Vollmer TL. Primary Angiitis of the Central Nervous System. MR Imaging in White Matter Diseases of the Brain and Spinal Cord (Medical Radiology/Diagnostic Imaging). Editors: M. Filippi, N DeStefano, V Dousset, and JC McGowan (2006).
Campagnolo D, Vollmer T, Shi F, Scott D, Williamson S. eMedicine Journal, January 9, 2006 ;7:1 (Sections 1 –12). Submitted.
Shi F, Campagnolo D, Vollmer T. Immune Therapy for Multiple Sclerosis: Altered Peptide Ligands and Statins. MS Handbook. Ed: S. Cook. Accepted.
Preiningerova J, Bomprezzi R, Vollmer T L, Waxman SG (June 2009) Multiple Sclerosis in: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. DOI:10,1002/9780470015902.a0000192.pub2.http://www.els.net
Bibliography—Abstracts and other presentations
Vollmer TL. Tausch G. Porteus M. Lim M. Steinman L. Antigen specific proliferation of T cells from the cerebrospinal fluid of patients with fungal meningitis. Presented at the 6th International Congress of Immunology, 1986. (In Abstracts from the 6th International Congress of Immunology,1986, p. 711.)
Young R. Vollmer TL. Farr K. Sena M. Genetic control of susceptibility to acute and persistent infection in trigeminal ganglia by herpes simplex virus. Presented at the American Academy of
19

3/13/12
Neurology 38th Annual Meeting, New Orleans, LA, 1986. (Abstract published in Neurology, 36,
Suppl. 1, 1986, p. 222.)
3. Young R. Vollmer TL. Farr K. Sena M. Genetic control of susceptibility to acute and persistent
infection in trigeminal ganglia by herpes simplex virus. Presented at the American Academy of Neurology 38th Annual Meeting, New Orleans, LA, 1986. (Abstract published in Neurology, 36, Suppl. 1, 1986, p. 222.)
4. Gjedde A. Leger G. Guttman M. Kuwabara H. Diksic M. Spencer DD. Naftolin F. Robbins RJ. Roth RH. Bunney B. Fatigue in multple sclerosis patients. Presented at the 19th Annual Meeting of the Society for Neuroscience, Phoenix, AZ, 1989. (Abstract published in Society for Neuroscience Abstracts, 15, 1989, p. 932.)
5. Ellsworth JD. Redmond DE Jr. Spencer DD. Vollmer TL. Marek KL. Naftolin F. Robbins RJ. Leranth C. Kier EL. Bunney BS. Roth RH. CSF HVA in Parkinsonian patients after fetal mesencephalic tissue implants into caudate nucleus. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992, p. 283.)
6. Redmond DE Jr. Marek KL. Spencer DD. Natfolin F. Robbins RJ. Bunney BS. Leranth C. Vollmer TL. Fahri AE. Ashby AMC. Lawrence MS. Serrano CC. Levy LL. Kier EL. Elsworth JD. Roth RH. Changes in motor performance after unilateral caudate implantation of fetal mesencephalic tissue. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992, p. 198.)
7. Marek KL. Spencer DD. Naftolin F. Robbins RJ. Roth RH. Bunney BS. Leranth C. Vollmer TL. Fahri AE. Serrano CC. Levy L. Sass KJ. Price LH. Redmond DE Jr. Clinical effects of implantation of the caudate nucleus with fetal mesencephalic tissue in four Parkinsonian patients. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992, p. 197.)
8. Spencer DD. Naftolin F. Robbins RJ. Roth RH. Bunney BS. Leranth C. Vollmer TL. Price LH. Kier EL. Marek KL. Gjedde A. Fahri AE. Redmond DE Jr. Effects of human fetal tissue grafts in four Parkinsonian patients. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992, p. 197.)
9. Klotz KL. Goldstein JM. Booss J. Lee J. Vollmer TL. Trafficking of immune cells into CNS: Sequence of phenotypes. Presented at the American Academy of Neurology 4
10. Goldstein JM. Klotz K. Booss J. Vollmer TL. A mouse model of CNS inflammation: The role of adhesion molecules. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992. p. 325.)
11. Vollmer TL. Dalton J. Klotz K. Goldstein JM. Astrocyte-lymphocyte binding: The role of immune cytokines and ICAM-1. Presented at the American Academy of Neurology 44th Annual Meeting, San Diego, CA, 1992. (Abstract published in Neurology, 42, Suppl. 3, 1992, p. 158.)
12. Lee JH. Vollmer TL. Ransom BR. Extracellular pH and epileptiform activity in rat hippocampal slices. Presented at the 23rd Annual Meeting of the Society for Neuroscience, Washington, DC, 1993. (In Society for Neuroscience Abstracts, 19, Part 3, 1993, p. 1870.)
13. Vollmer TL. Shellenberger MK. U.S. Tizanidine MS Study Group. Efficacy and safety of tizanidine for reduction of spasticity in multiple sclerosis. Presented at the American Academy of Neurology 46th Annual Meeting, Washington, DC, 1994. (Abstract published in Neurology, 44, 1994, p. A375.)
14. Cook SD. Newark NJ. Bansil S. Boos J. Devereau C. Haffty B. Goldstein JM. Guarnaccia J. Rohowsky-Kochan C. Sheffet A. Troiano R. Vollmer TL. Wolansky L. Zito G. Total lymphoid irradiation (TLI) and Low-Dose Prednisone (LDP) in progressive multiple sclerosis (PMS). Presented at the American Academy of Neurology 47th Annual Meeting, Seattle, WA, 1995. (Abstract published in Neurology, 45, Suppl. 4, 1995, p. A417.)
15. Schwartz C. Vollmer TL. Zeng Q. North American Research Consortium on Multiple Sclerosis. New outcome measures for multiple sclerosis clinical research: The symptom inventory and the
20
3/13/12
performance scales. Presented at the American Academy of Neurology 48th Annual Meeting, San
Francisco, CA, 1996. (Abstract published in Neurology, 46, Suppl. to #2, 1996, p. A321.)
16. Sheremata WA. Vollmer TL. Stone LA. Willmer-Hulme AJ. Koller ME. A placebo-controlled,
safety, tolerability, dose escalation, PK study of various doses of intravenous Antegren in patients with multiple sclerosis. Presented at the American Academy of Neurology 50th Annual Meeting, Minneapolis, MN, 1998. (Abstract published in Neurology, 50, Suppl. 4, 1998, pp. A63-A64.)
17. Bever CT Jr. Koller M. Hulme A. Walicke P. Vollmer TL. Sheremata W. Johnson K. Inter-rater variability in the scoring of the Scripps Neurological Rating Scale and the Expanded Disability Status Scale: Improvement with training. Presented at the 123rd Annual Meeting of the American Neurological Association, Montreal, Quebec, Canada, 1998. (Abstract published in the Program of the Annual Meeting, 1998.)
18. Vollmer TL. Safety and tolerability of glatiramer acetate for injection (formerly known as Copolymer-1) in the treatment of multiple sclerosis patients previously treated with interferon beta- 1b. Presented at the 123rd Annual Meeting of the American Neurological Association, Montreal, Quebec, Canada, 1998. (Abstract published in the Program of the Annual Meeting, 1998.)
19. Guarnaccia JB. Vollmer TL. Combination treatment regimens using interferon beta and immunosuppressive/ cytotoxic drugs in patients with multiple sclerosis. Presented at the 123rd Annual Meeting of the American Neurological Association, Montreal, Quebec, Canada, 1998. (Abstract published in the Program of the Annual Meeting, 1998, and in Annuals of Neurology, 44, 1998, p. W250.)
20. Sheremata WA. Minagar A. Hulme A. Koller M. Vollmer T. Reduction of relapses in multiple sclerosis after natalizumab (Antegren) treatment. Presented at the 123rd Annual Meeting of the American Neurological Association, Montreal, Quebec, Canada, 1998. (Abstract published in the Program of the Annual Meeting, 1998.)
21. Preiningerova J. Miyazaki T. Yu RK. Adelson K. Anderson A. Pukdaman N. Vollmer TL. The potential role of antibodies against glycosphinogolipids in axonal loss in multiple sclerosis. Presented at the American Academy of Neurology 51st Annual Meeting, Toronto, Ontario, Canada, 1999. (Abstract published in Neurology, 52, Suppl. 2, 1999, p. A399.)
22. Hadjimichael O. Vollmer TL. Adherence to injection therapy in multiple sclerosis: Patient survey. Presented at the American Academy of Neurology 51st Annual Meeting, Toronto, Ontario, Canada, 1999. (Abstract published in Neurology, 52, Suppl. 2, 1999, p. A549.)
23. Vollmer TL. Ni W. Hadjimichael O. Auld E. A study by the North American Research Consortium on Multiple Sclerosis (NARCOMS) of patients with multiple sclerosis in the Veterans Healthcare Administration (VHA) compared to the non-VHA population. Presented at the Rehabilitation In Multiple Sclerosis-Consortium of Multiple Sclerosis Centers (RIMS-CMSC) Joint Symposium, Basel, Switzerland, 1999. (Abstract published in Multiple Sclerosis, 5, Suppl. 1, 1999, p. S130.)
24. Vollmer TL. Ni W. Hadjimichael O. The North American Research Committee on Multiple Sclerosis Patient Registry: A progress report. Presented at the 15th Congress of the European Committee for Treatment and Research In Multiple Sclerosis / 4th Annual Meeting of America’s Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS / ACTRIMS 99), Basel, Switzerland, 1999. (Abstract published in Multiple Sclerosis, 5, Suppl. 1, 1999, p. S74.)
25. Vollmer TL. Hadjimichael O. Ni W. The cause of non-adherence to disease-course altering therapies: A comparative study. Presented at the 15th Congress of the European Committee for Treatment and Research in Multiple Sclerosis/ 4th Annual Meeting of America’s Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 99), Basel, Switzerland, 1999. (Abstract published in Multiple Sclerosis, 5, Suppl. 1, 1999, p. S97.)
26. Vollmer TL. Ni W. Hadjimichael O. Why are eligible patients with multiple sclerosis not on treatment with interferon beta or glatiramer acetate: Risk factors for non-treatment. Presented at the American Neurological Association 124th Annual Meeting, Seattle, WA, 1999. (Abstract published in Annuals of the 124th Annual Meeting of the American Neurological Association, 1999, p. 35.)
21
3/13/12
27. Vollmer TL. Ni W. Hadjimichael O. Utilization patterns of immunological therapies among VA patients with multiple sclerosis. Presented at the American Neurological Association 124th Annual Meeting, Seattle, WA, 1999. (Abstract published in Annals of the 124th Annual Meeting of the American Neurological Association, October 1999, p. 51.)
28. Cook SD. Quiniess JR. Jotkowitz A. Neutralizing Antibody Study Group. Neutralizing antibodies (Nab’s) to beta interferons in patients with multiple sclerosis. Presented at the American Academy of Neurology 52nd Annual Meeting, San Diego, CA, 2000. (Abstract published in Neurology, 54, Suppl. 3, 2000, p. A234.)
29. Vollmer TL. Ni W. Hadjimichael O. Multiple sclerosis treatment patterns at the end of the 20th century. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Halifax, Canada, June 2000. (Abstract published online [www.mscare.org] in the International Journal of MS Care, 2(2), 2000.)
30. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. Presented at Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Halifax, Canada, June 2000. (Abstract published online [www.mscare.org] in the International Journal of MS Care, 2(2), 2000.)
31. Vollmer TL. Hadjimichael O. Ni W. Effect of race in the treatment of multiple sclerosis. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Halifax, Canada, June 2000. (Abstract published online [www.mscare.org] in the International Journal of MS Care, 2(2), 2000.)
32. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001;33:231-239.
33. Vollmer TL. Ni W. Hadjimichael O. Subtypes of multiple sclerosis: Biological factors and progression of disease. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, May 2001. (Abstract published in Neurology, 56, Suppl. 3, 2001, pp. A194-195.)
34. Ni W. Hadjimichael O. Vollmer TL. Rizzo M. Pain syndromes in multiple sclerosis: Severity, impact on quality of life, and treatment patterns. Presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, May 2001. (Abstract published in Neurology, 56, Suppl. 3, 2001, p. A98.)
35. Vollmer TL. Ni W. Hadjimichael O. Rizzo M. Biological factors and subtypes of multiple sclerosis. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Fort Worth, TX, May 2001. (Abstract published in the International Journal of MS Care, 3, 2001, p. 51.)
36. Vollmer TL. Ni W. Hadjimichael O. Rizzo M. Disability and handicap in multiple sclerosis and their effect on employment. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Fort Worth, TX, May 2001. (Abstract published in the International Journal of MS Care, 3, 2001, p. 51.)
37. Ni W. Hadjimichael O. Rizzo M. Vollmer TL. The impact of childbirth on the progression of disability in multiple sclerosis. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Forth Worth, TX, May 2001. (Abstract published in the International Journal of MS Care, 3, 2001, p. 39.)
38. Preiningerova J, Ding Z, Cannistraci C, Sun H, Vollmer T, Anderson A. Computer Assisted Volumetric Analysis of Gadolinium Enhancement in Mulitple Sclerosis(P245). Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
39. Goodman A, Blight A, Cohen J, Cross A, Katz M, Rizzo M, Vollmer T. Placebo-Controlled Double-Blinded Dose Ranging Study of Fampridine-SR in Multiple Sclerosis(P308). Presented at the Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
22

3/13/12
40. Markovic-Plese S, Powell A, Cortez A, Vollmer T. Therapeutic Potential of Statins in Relapsing- Remitting Multiple Sclerosis(P340). Presented at the Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002
41. Goodman AD, Blight A, Cohen J, Cross A, Katz M, Rizzo MA, Vollmer TL. Placebo-controlled Double-Blinded Dose Ranging Study of Fampridine-SR in Multiple Sclerosis. ECTRIMS 2002
42. Goodman AD, Blight A, Cohen J, Cross A, Katz M, Rizzo MA, Vollmer TL. Placebo-controlled Double-Blinded Dose Ranging Study of Fampridine-SR in Multiple Sclerosis. AAN 2002
43. Rizzo M, Hadjimichael O, Buenconsejo J, Preiningerova J, Vollmer T. Spasticity in MS Patients in the NARCOMS Registry: Prevalence, Severity and Treatment Patterns Using Oral Agents And/Or Intrathecal Baclofen(P191). Presented at the Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
44. Vollmer TL, Hadjimichael O, Buenconsejo J. Quality of Life and Cost of Illness in Mitoxantrone Treated Multiple Sclerosis Patients(P185). Presented at the Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
45. Vollmer TL, Preiningerova J, Markovic-Plese S, Rizzo M, Cugger G. A Phase IIB Study of Oral Interferon Beta-1A At Two Doses in Relapsing Remitting Multiple Sclerosis Using MRI, Clinical and Immunologic Measures(P163). Presented at the Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
46. Marrie R, Cohen J, Hadjimichael O, Vollmer T. Use of Alternative Providers in Multiple Sclerosis(P63). Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Baltimore, MD, September 2002.
47. Goodman A, Cohen J, Vollmer T, Cohen R, Katz M, Blight A, Fampridine-SR Study Group. Safety and Efficacy of Fampridine-SR inMultiple Sclerosis Patients: a Phase 2 Trial. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), Toronto, Canada, June 2004.
48. Kasper L, Everitt D, Leist T, Ryan K, Mascelli M, Cusmano C, Johnson K, Hartnett H, Bauman T, Fadul C, Chanon-Smith J, Markovic S, Vollmer, T. Therapeutic Intervention of Multiple Sclerosis with an IL-12/23p40 Antagonist: A Phase I Clinical Trail. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Vienna, Austria, October 2004.
49. Vollmer T, Wymer J, Smith R, Pope L. A Randomized Trial of AVP-923 for Treatment of Pain in Multiple Sclerosis. Presented at the Consortium of Multiple Sclerosis Centers, Orlando, FL. June 2005.
50. Liu R, Van Kaer L, LaCava A, Price M, Campagnolo D, Collins M, Young D, Vollmer T, Shi F. Autoreactive T cells mediate NK cell degeneration in autoimmune disease.
51. Bar-Or A, Jalili F, Niino M, Bodner C, Antel J, Shi F, Price M, Rhodes S, Vollmer T, Gianettoni J, Valone F, Steinman L, Garren H. Antigen-specific Immune Changes with MBP Encoding DNA Plasmid (BHT-3009) alone or Combined with Atorvastatin Multiple Sclerosis Patients. Submitted
52. Bar-Or A, Jalili F, Niino M, Bodner C, Antel J, Shi F, Price M, Rhodes S, Vollmer T, Gianettoni J, Valone F, Steinman L, Garren H. Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Submitted
53. Liu R, LaCava A, Pollard M, Price M, Rhdoes S, Vollmr T, Sarvetnick N, Shi F. Impaired Neuroantigen Priming Determines Resistance to the Induction of Autoimunity in MyD88-Deficient Mice. Accepted AAN 2005 Meeting, Miami Beach, FL
54. Liu R, Pollard M, LaCava A, Price M, Rhodes S, Campagnolo D, Vollmer T, VanKear L, Shi F. Treatment of a B-Cell Mediated Autoimmune Disease, Myasthenia Gravis in Mice by Activation of Natural Killer T (NKT) Cells. Accepted AAN 2005 Meeting, Miami Beach, FL
55. Vollmer T, Lapierre Y, Weiner L, Oger J, Bar-Or A, Arnold D, Barkas W, Antel J, Kachuck N, Garren H, Gianettoni J, Steinman L, Valone F; Clinical trial of a MBP encoding DNA plasmid (BHT- 3009) alone or combined with atorvastatin for treatment of multiple sclerosis. Accepted ECTRIMS/ACTRIMS 2005 meeting, Thessaloniki, Greece.
23
3/13/12
56. Vollmer T, Panitch H, Dunn S, Lublin F, O'Connor P, Bar-Or A, Freedman M, Hendin B, Gazda S, Campagnolo D, Shi F. Induction treatment with mitoxantrone (Novantrone®) preceding treatment with glatiramer acetate (Copaxone®), a multi-centre, randomised, two-arm, open-label study in RRMS patients. Accepted ECTRIMS/ACTRIMS 2005 meeting, Thessaloniki, Greece.
57. Bar-Or A, Jalili F, Niino M, Bodner C, Antel J, Shi F, Price M, Rhodes S, Vollmer T, Gianettoni J, Valone F, Steinman L, Garren H. Antigen-specific Immune Changes with MBP Encoding DNA Plasmid (BHT-3009) alone or Combined with Atorvastatin Multiple Sclerosis Patients. Submitted.
58. Garren H, Antel J, Bar-Or A, Bodner C, Campagnolo D, Gianettoni J, Jahili F, Kachuck N, Lapierre Y, Nino M, Oger J, Price M, Rhodes S, Shi F, Valone F, Vollmer T, Weiner L, Steinman L. Phase I/II trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin for treatment of multiple sclerosis. European Neurological Society 2006 Annual Meeting; Lausanne, Switzerland.
59. Garren H, Antel J, Bar-Or A, Bdner C, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson W, Shi F, Valone F, Vollmer T, Steinman L. Phase I/II trial of a MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin for treatment of MS. International Society of Neuroimmunology 2006 Annual Meeting; Nagoya, Japan.
60. Hadjimichael, O., Kerns, R., Rizzo M., Vollmer T. (2007). Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain, 127, 1-2, 35-41
61. Bar-Or A, Gibbs E, Niino M, Aziz T, Alatab S, Shi F, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman M, Panitch H, Arnold D, Vollmer T, Oger J. Tracking in vivo immune modulation in MS patients treated with Glatiramer Acetate (GA) alone, or with GA preceded by Mitoxantrone, provides novel insights into the mode of action of therapeutic strategies that combine immune suppression and immune deviation. Neurology 2007 March 20:68(12);S1.
62. Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R, Bar-Or A, Sarkar N, Langer-Gould A, Panzara M, Smith C. A phase II randomized, placebo-controlled multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). Neurology 2007 March 20:68(12);S1.
63. Cutter G, Yadavalli R, Marrie R, Tyry T, Campagnolo D, Bullock B, Vollmer T. Changes in the sex ratio over time in multiple sclerosis. Neurology 2007 March 20:68(12);S1.
64. Bullock B, Tyry T, Cutter G, Marrie R, Vollmer T, Campagnolo D. Birthplace variation among US residents with MS. Neurology 2007 March 20:68(12);S1.
65. Marrie R, Cutter G, Tyry T, Vollmer T, Campagnolo D. Patients with multiple sclerosis smoke more than the general population. Neurology 2007 March 20:68(12);S1.
66. Bullock B, Tyry T, Cutter G, Marrie R, Vollmer T, Campagnolo D. Seasonal patterns of birth in NARCOMS MS registry. Neurology 2007 March 20:68(12);S1.
67. Vollmer T, Campagnolo D, Panitch H, Bar-Or A, Arnold D. Reductions in MRI disease activity and relapse rates in observed after induction of shortterm immunosuppression with mitoxantrone followed by longterm glatiramer acetate (GA) are maintained at 24 months in patients with relapsing remitting multiple sclerosis (RRMS). Neurology 2007 March 20:68(12);S1.
68. Arnold D, Bar-Or A, Freedman M, Gazda S, Panitch H, Vollmer T. Reductions in Gd enhancing lesions observed with glatiramer acetate following a brief and low dose course of mitoxantrone in patients with relapsing remitting multiple sclerosis (RRMS) are paralleled by favorable effects on MRI markers of disease burden and black hole evolution. Neurology 2007 March 20:68(12);S1.
69. Foley F, Zemon V, Campagnolo D, Marrie RA, Cutter G, Tyry T, Devitt M, Miller T, Sipski M, and Vollmer T. (2007). Validation of the MS Intimacy and Sexuality Questionnaire in large national sample. Poster S33 Presented at the 21st Annual CMSC Meeting in Washington, DC, June, 2007. (Abstract published in International Journal of MS Care, 9,2, 58-59.)
70. Foley F, Zemon V, Campagnolo D, Devitt M, Tyry T, Marrie RA, Cutter G, Sipski M, & Vollmer T. (2007). The Epidemiology of sexual dysfucntion in multiple sclerosis in the United States. Platform presentation P15 at the 21st Annual CMSC Meeting in Washington, DC, June 2007. (Abstract published in International Journal of MS Care, 9,2, 47-48.)
24
3/13/12
71. Hadjimichael, O, Vollmer, T, Oleen-Burkey, M (2008). Fatigue characteristes in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health and Quality of Life Outcomes, 6, 100.
72. Moberly J, Zahir H, Ford D, Truitt, KE, Carothers, TJ, Chen, S, Shi M, Vollmer T An adaptive multiple Ascending dose study using lymphocytes as a primary biomarker for early clinical evaluation of a S1P receptor Modulator for treatment of multiple sclerosis ACTRIMS 2009
73. Eckert B, Smith KW, Trisolini M, Vollmer T Prescription Medication use among MS adults on disease Modifying therapies. CMSC Abstract #2 January 22, 2009.
74. Eckert B, Smith KW, Trisolini M, Vollmer T Burden of Disease-Modifying therapy injections administration for MS caregivers. CMSC Abstract #1 January 22, 2009.
75. Tyry, T., Vollmer, T., Davis, P., Marrie, R.A., Cutter, G., & Campagnolo, D. (2008) Natural history of MS Among patients treated with SC interferon B-1b. Poster S87 presented at the CMSC conference in Denver, May 2008. (Abstract published in International journal of MS Care, 10, S1, 38.) MS caregivers. CMSC Abstract #1 January 22, 2009.
76. Salter AS, Tyry T, Moreau R, Marrie RA, Vollmer T, Cutter, GR. (2010) Estimating the Probability of Employment Status Transitions and Exploration of Influential Factors. Poster presentation 2010 AAN Annual Meeting Toronto.
77. Moreau R, Salter A, Tyry T, Marrie RA, Vollmer T, Cutter GR. (2010) Hand Function, Mobility and Employment Status in the NARCOMS Registry. Abstract presented at the 2010 AAN annual meeting Toronto.
78. Volmer T, Bar-Or A, Campagnolo D, Panitch H, and Arnold D. (2010) Short-term Immunosuppression with Mitoxantrone Followed by Long-Term Glatiramer Acetate vs Glatiramer Acetate Alone: Results at 60 Months in Patients with Relapsing Multiple Sclerosis. Abstract,2010 American Academy of Neurology annual meeting, Toronto, Canada
79. Zahir H, Moberly JB, Ford D, Truitt KE, Bar-Or A, Vollmer T. (2010) Differential effects of a selective sphingosine1-phosphate receptor 1 (S1P1) Modulator (CS-0777) on circulating lymphocyte subsets in multiple sclerosis patients. Poster presentation 2010 AAN annual meeting.
80. Calabresi PA, Goodin D, Jeffrey D, Lublin FD, Rammohan K, Reder AT, Vollmer T, Stites T, Li B, Gottschalk R and Malhotra M on behalf of the FREEDOMS II Study Group. (2010) Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baselilne patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS II). Abstract/Poster presentation given at 2010 AAN annual meeting, Toronto; also presented at the Annual CMSC Meeting, June, 2010, San Antonio, TX
81. Ramesh CN, Vollmer T, Bomprezzi R, Campagnolo D, Jacolik R. A relative deficiency in CD16+/Perforin + Lymphocytes (NK cells) in multiple sclerosis is corrected by glatiramer acetate (GA) treatment. Abstract given at ACTRIMS meeting San Antonio, TX June, 2010
82. Ramesh CN, Vollmer TL, Bomprezzi R, Campagnolo D and Jocolik R. Plasma visfatin elevation in multiple Sclerosis. Abstract given at ACTRIMS meeting, San Antonio, TX June, 2010
83. Marrie, RA, Cutter G, Vollmer T, and Tyry T. Physical Comorbidities Are Associated with an Increased Risk of Depression in Multiple Sclerosis. Abstract accepted, American Academy of Neurology Annual Meeting Toronto, Canada 2010.
84. Marrie RA, Cutter G, Vollmer T, and Tyry T. Comorbidity is Associated with Greater Decrements in Quality of Life over Two Years in MS. Abstract #264AAN10D1 American Academy of Neurology Annual Meeting Toronto, Canada 2010
85. Campagnolo, D, Bomprezzi R, Vollmer T. Recirculating phagocytes are a novel source of biomarkers for multiple sclerosis. Abstract C-99 accepted for presentation to the American Academy of Clinical Chemistry annual meeting in Anaheim, CA July, 2010
86. Schmidt H, Loud S, Venkatesan A, Goins J, Frohman E, Taylor S, Sadiq S, Puccio L, Thrower B, Iski E, Riskind P, Weaver J, Bomprezzi R, Bullock B, Kinkel RP, Konkel S, Racke M, McGowan J, Vollmer T, Edward S, Steinman L, Lebus D, Greenberg B. The Accelerated Cure Project Biorepository—enabling the discovery of biomarkers in MS and other demyelinating diseases. Poster
25
3/13/12
P963 presented at The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 15th Annual conference of Rehabilitation in MS October 12—16, 2010, Gothenburg, Sweden.
87. Salter AR, Cofield SS, Vollmer T, Cutter GR. Timing of birth in United States-born multiple sclerosis population. Poster P617 presented at The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 15th Annual conference of Rehabilitation in MS October 12—16, 2010, Gothenburg, Sweden.
88. “Return to ECTRIMS: Updates from ECTRIMS for Treatment and Research in MS” to area Neurologists, Denver, Colorado February 23, 2011.
89. Vollmer, TL, Tyry, T, Salter A, Cutter G, Marrie R. Is trigeminal neuralgia more prevalent in certain groups of multiple sclerosis patients? Poster presentation to the AAN Annual meeting, Honolulu, HI April, 2011.
90. Fox R, Salter A, Alster JM, Cutter G, Dawson NV, Johnson S, Miller D, Tyry T, Vollmer T, Wells B, Kattan M. Do multiple sclerosis patients understand Risk? Survey results from the NARCOMS Registry. Poster presentation at the AAN annual meeting, Honolulu, Hawaii, April, 2011
91. Moreau RL, Salter AR, Marrie R, Tyry T, Cutter G, Vollmer T. Comorbidities, smoking habits, and their connection with secondhand smoke. Poster presentation to the AAN annual meeting, Honolulu, Hawaii, April, 2011
92. Miller D, Alster JM, Cutter G, Dawson NV, Johnson S, Kattan M, Salter A, Tyry T, Wells B, Vollmer T, Fox R. Patient preferences for information seeking and decision resources: survey results from the NARCOMS registry. Poster presentation to the AAN annual meeting, Honolulu, Hawaii, April, 2011
93. Fox R, Salter A, Alster JM Dawson NV, Johnson S, Kattan M, Miller D, Tyry T, Wells B, Vollmer T, Cutter G. Risk tolerance in MS patients: survey results from the NARCOMS registry. Poster presentation to the AAN annual meeting Honolulu, Hawaii, April, 2011
94. Vollmer TL, Robinson MR, Risser RC, Malcolm SK, Carlson JL. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of central neuropathic pain associated with multiple sclerosis. Poster presented at the annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) annual meeting. Amsterdam, The Netherlands, October 21, 2011.
95. Vollmer TL, Sorensen PS, Arnold DL on behalf of the BRAVO Study Group. A Placebo-Controlled and Active Comparator Phase III Trial (BRAVO) for Relapsing-Remitting Multiple Sclerosis. Poster presented at the Annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis)annual meeting, Amsterdam, The Netherlands on October 22, 2011.
96. Nayak R, Vollmer T, Bomprezzi R, Jacolik R. A circulating biomarker for the therapeutic response in multiple sclerosis. Poster presentation ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) annual meeting in Amsterdam, The Netherlands
October 21, 2011
97. Volmer T, Comi G, Sorensen PS, Arnold D, Filippi M, Statinova O, Kobys t, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Clinical efficacy of laquinimod for the treatment of multiple Sclerosis; pooled analyses from the ALLEGRO and BRAVO Phase III trials. Poster and abstract presented at the 64th Annual American Academy of Neurology meeting, New Orleans, LA April 24, 2012
98. Comi G, Vollmer T, Sorensen PS, Arnold D, Filippi M, Statinov O, Kobys T, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment. Abstract and poster presented at the 64th Annual American Academy of Neurology Meeting, New Orleas, LA April 25, 2012.
99. Campbell J, McQueen RB, Corboy J, Vollmer T, Nair K. New versus old: long-term comparative effectiveness research projections for disease modifying therapies in relapsing-remitting multiple sclerosis. Abstract and poster presented at 64th Annual American Academy of Neurology meeting, New Orleans, LA April 26, 2012.
26
3/13/12
100. Vollmer T, Due B. A double-blind, placebo-controlled, phase2, 26-week DreaMS trial of a selective S1P receptor agnonists ONO 4641 in patients with relapsing-remitting multiple sclerosis. Abstract and poster presentation at the 64th Annual American Academy of Neurology meeting, New Orleans, LA, April 25, 2012
13.4
Bibliography—Non peer reviewed publications
1. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 1999. 18(2):2
2. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 1999. 18(3):2.
3. Vollmer TL. Mitoxantrone: A New Treatment for Multiple Sclerosis. Multiple Sclerosis Quarterly
Report. 1999. 18(4):1, 3-5
4. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 1999. 18(4):2
5. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2000. 19(1):2.
6. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2000. 19(4):2.
7. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2000. 19(3):2.
8. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2000. 19(2):2.
9. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2001. 20(4):2.
10. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2001. 20(2):2.
11. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2001. 20(1):2.
12. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2001. 20(3):2.
13. Vollmer TL. The Changing Definition of Multiple Sclerosis. Multiple Sclerosis Quarterly Report.
2001. 20(3):24-25.
14. Vollmer TL. Ethical Considerations of Clinical Trials in Multiple Sclerosis Treatment. Multiple

Sclerosis Quarterly Report. 2001. 20(3):21-23.
15. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2002. 21(1):2.
16. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2002. 21(2):2
17. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2002. 21(3):2
18. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2002. 21(4):2.
19. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2003. 22(1):2
20. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2003. 22(2):2.
21. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2003. 22(3):2
22. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2003. 22(4):2
23. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2004. 23(1
24. Vollmer TL. Letter from the Editor. Multiple Sclerosis Quarterly Report. 2004. 23(2):2
14. Patents Held
Nicotinic Attenuation of CNS Inflammation and Autoimmunity U.S. Application No. 13/063,713, which is the national phase of International PCT Patent Application No. PCT/US09/56671, an application claiming the benefit of U.S. Prov. App. No. 61/096,170
27

Labels: Avonex, Betaseron, Copaxone, Novantrone, Rebif, Rituxan, Tysabri